

---

**International Symposium**

**ACUTE LEUKEMIAS XVI**  
**Biology and Treatment Strategies**

organized by

**German AML Cooperative Group (AMLCG)**

**SFB 1243: Genetic and Epigenetic Evolution  
of Hematopoietic Neoplasms**

and

**German Consortium for Translational Cancer Research (DKTK)**

together with

Ludwig Maximilians-University Munich (LMU)

German Cancer Research Center (DKFZ)

HelmholtzZentrum München

German Research Center for Environmental Health

Comprehensive Cancer Center Munich (CCCMünchen)

German Society for Hematology and Medical Oncology (DGHO)

Working Group Internistische Onkologie  
in der Deutschen Krebsgesellschaft e.V. (AIO)

ELN Foundation – European ■ LeukemiaNet

and

**Verein für Leukämieforschung und –Therapie e.V.**

**February 19 – February 22, 2017**  
**Munich, Germany**

*Best of Free  
Contributions  
Awards 2017*

*Poster Awards  
2017*

*Leukemia Clinical  
Research Award  
2017*

**PROGRAM**

---



# ACUTE LEUKEMIAS XVI

## Biology and Treatment Strategies

---

### Organisation in Charge:




Verein für Leukämieforschung und -Therapie e.V.  
Münster

### Cooperating Institutions:



German AML Cooperative Group  
(AMLCG)



SFB 1243: Genetic and Epigenetic Evolution  
of Hematopoietic Neoplasms

LMU

Klinikum der Universität München  
Medizinische Klinik und Poliklinik III



German Consortium for Translational Cancer  
Research (DKTK)



German Cancer Research Center - Deutsches  
Krebsforschungszentrum (DKFZ)



HelmholtzZentrum München - German Research  
Center for Environmental Health



Comprehensive Cancer Center München  
(CCC München)



German Society for Hematology and Medical  
Oncology (DGHO)




Working Group Internistische Onkologie in der  
Deutschen Krebsgesellschaft e.V. (AIO)



ELN Foundation – European ■ LeukemiaNet

---



Dear Colleagues:

The German AML Cooperative Group invites all professionals who are interested in getting informed about recent advances in the understanding of leukemia biology and the development of a personalized approach to leukemia therapy and the implementation of new discoveries into clinical practice to participate in the 16<sup>th</sup> International Symposium on ACUTE LEUKEMIAS held in Munich, February 19 – 22, 2017.

The symposium will again bring together a unique community of clinical scientists and researchers and will render all attendees the opportunity to discuss the most recent findings in basic research and results of clinical studies and network with the top international experts in these fields.

The scientific program will start on Sunday, February 19 with a main focus on basic research while the following days will concentrate on translational research and clinical studies.

You are cordially invited to use this forum to become updated on recent developments in the complex field of leukemia research and therapy. You may also take the opportunity to present your own data in the context of the poster and the best of free contribution sessions.

Satellite Symposia and Meet-the-Professor Sessions will deliver further chances to discuss advances and perspectives of basic science and treatment strategies.

The organizing committee and I are looking forward to an exciting Symposium on ACUTE LEUKEMIAS and I will be pleased to welcome you in Munich.

Yours

W. Hiddemann



---

**SYMPOSIUM CHAIRMEN:**

Prof. Dr. W. Hiddemann, Munich

Prof. Dr. Th. Büchner, Münster †

**SCIENTIFIC ORGANIZING COMMITTEE**

Prof. Dr. W. Hiddemann, Munich

Prof. Dr. M. Fiegl, Munich

Prof. Dr. Th. Büchner, Münster †

Dr. K. Metzeler, Munich

Prof. Dr. I. Jeremias, Munich

Prof. Dr. K. Spiekermann, Munich

Prof. Dr. M. Subklewe, Munich

**NATIONAL SCIENTIFIC COMMITTEE**

Prof. Dr. C.D. Baldus, Berlin

Prof. Dr. K.A. Kreuzer, Cologne

Prof. Dr. D. Beelen, Essen

PD Dr. U. Krug, Leverkusen

PD Dr. Ch. Brandts, Frankfurt a.M.

Prof. Dr. H. Leonhardt, Munich

Prof. Dr. C. Buske, Ulm

Prof. Dr. C. Müller-Tidow, Heidelberg

Prof. Dr. H. Döhner, Ulm

Prof. Dr. D. Niederwieser, Leipzig

Prof. Dr. J. Duyster, Freiburg

Prof. Dr. D. Reinhardt, Essen

Prof. Dr. G. Ehninger, Dresden

Prof. Dr. M. Schrappe, Kiel

Prof. Dr. T. Feuchtinger, Munich

Prof. Dr. H. Serve, Frankfurt

Dr. N. Gökbüget, Frankfurt

Prof. Dr. M. Stelljes, Münster

Prof. Dr. K. Götze, Munich

Prof. Dr. Ch. Thiede, Dresden

Prof. Dr. W. Herr, Regensburg

Prof. Dr. A. Trumpp, Heidelberg

Prof. Dr. D. Hoelzer, Frankfurt

Prof. Dr. B. Wörmann, Berlin

Prof. Dr. W.K. Hofmann, Mannheim

**INTERNATIONAL SCIENTIFIC COMMITTEE**

Prof. Dr. M. Andreeff, Houston, USA

Prof. Dr. R.A. Larson, Chicago, USA

Prof. Dr. S.A. Armstrong, New York, USA

Prof. Dr. F. Lo-Coco, Rome, I

Prof. Dr. C. Bloomfield, Columbus, USA

Prof. Dr. B. Löwenberg, Rotterdam, NL

Prof. Dr. A.K. Burnett, Cardiff, UK

Prof. Dr. M. Manz, Zurich, CH

Prof. Dr. R. Champlin, Houston, USA

Prof. Dr. G.M. Ossenkoppele, Amsterdam, NL

Prof. Dr. H. Dombret, Paris, F

Prof. Dr. G. Roboz, New York, USA

Prof. Dr. E.H. Estey, Seattle, USA

Prof. Dr. M. Sadelain, New York, USA

Prof. Dr. P. Fenaux, Bobigny, F

Prof. Dr. M. Sanz, Valencia, E

Prof. Dr. W. Fibbe, Leiden, NL

Prof. Dr. C.A. Schiffer, Detroit, USA

Prof. Dr. D.J. Grimwade, London, UK †

Prof. Dr. P. Sonneveld, Rotterdam, NL

Prof. Dr. H. Kantarjian, Houston, USA

Prof. Dr. R. Stone, Boston, USA

Prof. Dr. G. Kvalheim, Oslo, NO

Prof. Dr. M. Tallman, New York, USA

---



---

**POSTER AWARD COMMITTEE**

Prof. Dr. K. Götze, Munich, DE

Prof. Dr. J. Rowe, Haifa, IL

**LEUKEMIA CLINICAL RESEARCH AWARD COMMITTEE**

Prof. Dr. C. Baldus, Berlin, DE

Prof. Dr. H. Döhner, Ulm, DE

Prof. Dr. U. Platzbecker, Dresden, DE

Further members to be announced later

Prof. Dr. Dirk Reinhardt, Essen, DE

Prof. Dr. B. Wörmann, Berlin, DE

**ORGANIZING OFFICE:**

Beate Buske-Kosel, M.A.

Am Webstuhl 5

D-59227 Ahlen

Germany

**Phone:** +49-(0)2382-76 01 457

**Fax:** +49-(0)2382-76 01 458

**Email:** [info@acute-leukemias.de](mailto:info@acute-leukemias.de)

**2**

**COORDINATING OFFICE:**

Doris Braun

**Phone:** +49-89-4400 43986

**Fax:** +49-89-4400 43970

**Email:** [Doris.Braun@med.uni-muenchen.de](mailto:Doris.Braun@med.uni-muenchen.de)

---



## **MAIN TOPICS**

**Epigenetic Changes in Acute Leukemias**

**Characterization of Leukemic Stem Cells**

**Clonal Evolution of Acute Leukemias**

**Genetic and Molecular Characterization of AML:  
Novel Markers for Diagnosis and Prognosis**

**Novel Approaches and Targeted Therapies in AML**

**Risk adapted Therapy of AML**

**Therapy of APL**

**Relevance of MRD in Acute Leukemias**

**Immunotherapy for Acute Leukemias**

**ALL: Biology and Treatment Strategies**



---

**TOPICS for FREE CONTRIBUTIONS**

**Leukemic Stem Cells**

**AML – Biology**

**AML – Therapy**

**ALL – Biology**

**ALL - Therapy**

**APL – Therapy**

**Pediatric Acute Leukemias**

**Immunotherapy of Acute Leukemias**

**Stem Cell Transplantation**

**Management of Elderly and Frail Patients**

**Supportive Therapy and Quality of Life**

**Leukemia Microenvironment**

---



**SCIENTIFIC PROGRAM**  
at a glance

**Sunday, February 19, 2017**

**10.00-12.00** **AGIHO Educational Symposium** (Lecture Hall V)  
(Infectious Diseases Working Party of the DGHO)

**Sunday, February 19, 2017**

**12.30-14.10** **MS I:** Epigenetic Changes in Acute Leukemias  
**14.40-16.40** **MS II:** Clonal Evolution and Leukemic Stem Cells  
**17.00-18.00** **Satellite Symposium I**  
**18.15-19.15** **Satellite Symposium II**

**Monday, February 20, 2017**

**08.30-08.45** **Welcome Address**  
**08.45-10.45** **MS III:** Genetic and Molecular Characterization of AML:  
Novel Markers for Diagnosis and Prognosis  
**11.15-12.00** **SPECIAL LECTURE**  
**12.45-13.45** **Satellite Symposium III**  
**13.00-13.45** **MTP I**  
**13.45-15.45** **MS IV:** Novel Approaches and Targeted Therapies in AML  
**15.45-17.00** **Main Session V:** Poster Discussion  
**16.30-18.00** **Satellite Symposium IV**  
**18.15-19.15** **Satellite Symposium V**

**Tuesday, February 21, 2017**

**08.30-10.30** **MS VI:** Risk Adapted Therapy of AML  
**10.50-12.30** **MS VII:** Biology and Treatment of APL  
**13.15-13.45** **MTP II**  
**14.00-15.40** **MS VIII:** Relevance of MRD in Acute Leukemias  
**16.15-17.30** **MS IX:** Prize Giving Ceremony *Leukemia Clinical Research Award*;  
Poster Awards and 3 of Best Free Contributions  
**16.30-17.30** **Satellite Symposium VI**  
**17.45-18.45** **Satellite Symposium VII**

**Wednesday, February 22, 2017**

**08.30-10.30** **MS X:** Immunotherapy for Acute Leukemias  
**11.00-12.40** **MS XI:** Biology and Treatment Strategies of ALL  
**12.40-13.00** **Closing Remarks**

Last updated February 3, 2017  
Adjustment and change of itinerary and program remain reserved!





---

**FACULTY**

**INVITED SPEAKERS** (alphabetical order)

Bargou, R., Würzburg, DE	MS X
Bejar, R., La Jolla, CA, USA	MS III
Berdel, W.E., Münster, DE	SAT VI (tbc)
Bloomfield, C., Columbus, OH, USA	MS VI
Bonnet, D., London, UK	MS II
Bornhäuser, M. Dresden, DE	MS VI
Brüggemann, M., Kiel, DE	MS VIII
Buske, Ch., Ulm, DE	MS II
Byrd, J., Columbus, OH, USA	MS III
Champlin, R.E., Houston, TX, USA	MS VI
Chan, L., San Francisco, USA^	MS IX (BoFC)
Churpek, J.E., Chicago, IL, USA	MS III
Daver, N., Houston, TX, USA	MS X
Delwel, R., Rotterdam, NL	MS I
De Thé, H., Paris, F	MS VII
DiPersio, St. Louis, MO, USA	MS X
Döhner, H., Ulm, DE	MS VI
Dolstra, H., Nijmegen, NL	MS X
Estey, E.H., Seattle, WA, USA	MS IV
Farge, Th., Toulouse, F	MS IX (BoFC)
Fenaux, P., Bobigny, F	SAT IV
Freeman, S., Birmingham, UK	MS VIII
Garrett Bakelman, F.E., New York, USA	MS I
Gökbuget, N., Frankfurt, DE	MS XI, SAT I, SAT II
Griesshammer, Martin, Minden, DE	SAT I
Groenbaek, K., Copenhagen, DK	SAT VI
Hellstrand, K. Gothenburg, SE	SAT III
Herold, T., Munich, DE	MS III
Hiddemann, W., Munich, DE	AGIHO, SPECIAL LECTURE
Ivey, A., Melbourne, AU	MS VIII
Kantarjian, H., Houston, TX, USA	MS XI, SAT VII
Köhnke, Th., Munich, DE	MS VIII
Konopleva, M., Houston, TX, USA	MS IV
Krug, U., Leverkusen, DE	SATVI

---



---

**FACULTY**

**INVITED SPEAKERS** (alphabetical order)

Lengfelder, E., Mannheim, DE	MS VII
Levis, M.J., Baltimore, MD, USA	MS IV
Lo Coco, Rome, I	MS VII
Majeti, R., Stanford, CA, USA	MS I
Maschmeyer, G., Potsdam, DE	AGIHO
Metzeler, K., Munich, DE	MS III
Montesinos, P., Valencia, E	MS VII
Müller-Tidow, C., Heidelberg, DE	MS I
Mullighan, Ch., Memphis, TN, USA	MS XI
Ossenkoppele, G., Amsterdam, NL	SAT V
Ostermann, H., Munich, DE	AGIHO
Pamer, E.G., New York, NY, USA	AGIHO
Papaemmanuil, E., New York, NY, USA	MS III
Park, J., New York, NY, USA	MS X
Plass, Ch., Heidelberg, DE	MS I
Roboz, G.J., New York, NY, USA	MS IV, SAT V
Rowe, J., Jerusalem, IL	SAT III
Russell, N.G., Nottingham, UK	MS VI; MS VII
Schlenk, R.F., Heidelberg, DE	MTP II
Schneider, D., Hannover, DE	MS IX (BoFC)
Schrappé, M., Kiel, DE	MS XI
Shlush, L., Rehovot, IL	MS II
Spiekermann, Munich, DE	MS VI
Stone, R.M., Boston, MA, USA	MS IV
Subklewe, M., Munich, DE	MS X, SATII
Tallman, M.S., New York, NY, USA	MS IV
Thol, F., Hannover, DE	SAT VI
Tischer, J., Munich, DE	MS XI
von Lilienfeld-Toal, M., Jena, DE	AGIHO
Walter, M.J., St. Louis, MO, USA	MS II
Walter, R.B., Seattle, WA, USA	MS VIII
Welch, J.S., St. Louis, MO, USA	MS II
Zimran; Ari, Jerusalem, IL	SAT I

---



---

**FACULTY**

**INVITED CHAIRPERSONS** (alphabetical order)

Bloomfield, C., Columbus, OH, USA	SPECIAL LECTURE
Dombret, H., Paris, F	MS IV
Ehninger, G., Dresden, DE	MS X
Enard, W., Munich, DE	MS II
Fenaux, P., Bobigny, F	MS VII, SAT IV
Fibbe, W.E., Leiden, NL	MS I
Gale, R.P., Los Angeles, CA, USA	MS VI
Götze, K., Munich, DE	Poster Session Award Committee
Hehlmann, R., Mannheim, DE	MS IX
Hiddemann, W., Munich, DE	SATI/SATIII/SATV/SATVI/SATVII
Hoelzer, D., Frankfurt a.M., DE	MS XI, SAT II
Hofmann, W.,K., Mannheim, DE	MS VII
Jeremias, I., Munich, DE	MS IV
Kreuzer, K.-A., Cologne, DE	MS VIII
Leonhardt, Martinsried, DE	MS I
Löwenberg, B., Rotterdam, NL	MS III
Maschmeyer, G. Potsdam, DE	AGIHO
Peschel, Ch., Munich, DE	MS X
Ritter, J., Münster, DE	MS IX
Rowe, J., Jerusalem, IL	Poster Session Award Committee
Schiffer, Ch.A., Detroit, IL, USA	MS XI
Schlenk, R.F., Heidelberg, DE	SAT IV
Schuurhuis, G.J., Amsterdam, NL	MS VIII
Serve, H., Frankfurt, DE	MS III
Tallman, M.S., New York, NY, USA	MS VI
Wei, A., Melbourne, AUS	MS II

---



**SUNDAY, February 19, 2017**

**EDUCATIONAL SYMPOSIUM of the AGIHO**  
*(supported by a grant by GILEAD Sciences GmbH)*

**10.00-12.00 Interdisciplinary Educational Symposium**  
*Arbeitsgemeinschaft Infektionen der DGHO (AGIHO)*  
*(Infectious Diseases Working Party of the DGHO)*  
**(Lecture Hall V)**

**Co-Chairs:**

*G. Maschmeyer, Potsdam, DE*  
*H. Ostermann, Munich, DE*

**10.00-10.15 W. Hiddemann, Munich, DE**  
*Development of AGIHO*

**10.15-10.45 G. Maschmeyer, Potsdam, DE**  
*20 Years AGIHO – Activities and Accomplishments*

**10.45-11.15 M. von Lilienfeld-Toal, Jena, DE**  
*Challenges in Infectious Diseases for Hematologists*

**11.15-12.00 E.G. Pamer, New York, NY, USA**  
*Microbiota-Mediated Defense against Intestinal Infection*

**12.00-12.30 COFFEE BREAK**

---



---

**SUNDAY**, February 19, 2017

**MAIN PROGRAM**

**12.30-14.10 MS I: Epigenetic Changes in Acute Leukemias**

*(Lecture Hall III/IV)*

**Co-Chairs:**

H. Leonhardt, Martinsried, DE

W.E. Fibbe, Leiden, NL

**12.30-12.50 F.E. Garret Bakelman, New York, NY, USA**

*Epigenetic Changes in Relapsed Acute Myeloid Leukemia*

**12.50-13.10 R. Majeti, Stanford, CA, USA**

*Leukemia-Associated Cohesion Mutations Enforce HSC Programs*

**13.10-13.30 Ch. Plass, Heidelberg, DE**

*DNMT and HDAC Inhibitors Globally Induce Cryptic TSSs Encoded In Long Terminal Repeats*

**13.30-13.50 C. Müller-Tidow, Heidelberg, DE**

*Stemness and Drug Resistance in AML*

**13.50-14.10 R. Delwel, Rotterdam, NL**

*Enhancer Defects in AML*

**14.10-14.40 COFFEE BREAK**

---



**SUNDAY**, February 19, 2017

**14.40-16.40 MS II: Clonal Evolution and Leukemic Stem Cells**  
*(Lecture Hall III/IV)*

**Co-Chairs:**

W. Enard, Munich, DE

A. Wei, Melbourne, AUS

**14.40-15.00 Ch. Buske, Ulm, DE**  
*Role of Early Developmental Genes in AML*

**15.00-15.20 J.S. Welch, St. Louis, MO, USA**  
*Origin of Mutations in Acute Myeloid Leukemia*

**15.20-15.40 L. Shlush, Rehovot, IL**  
*Clonal Evolution in Leukemia*

**15.40-16.00 M.J. Walter, St. Louis, MO, USA**  
*Clonal Architecture of Secondary AML*

**16.00-16.20 D. Bonnet, London UK**  
*Remodelling of Mesenchymal Stromal Niche by Acute Myeloid Leukemia*

**16.20-16.40 Discussion**

**16.40-17.00 COFFEE BREAK**

---



**SUNDAY**, February 19, 2017

**17.00-18.00 SATELLITE SYMPOSIUM I**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***Rare Diseases in Hematology***

**Chair:**

W. Hiddemann, Munich, DE

**M. Griesshammer, Minden, DE**

*Therapeutic Options of Essential Thrombocythemia  
and Perspectives*

**A. Zimran, Jerusalem, IL**

*Why Hematologists Should Care about Gaucher Disease*

**N. Gökbüget, Frankfurt, DE**

*Experience with PEG-Asparaginase in Adult ALL*

**18.00-18.15 COFFEE BREAK**



**SUNDAY**, February 19, 2017

**18.15-19.15 SATELLITE SYMPOSIUM II**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***Novel Treatment Strategies in Acute Leukemias:  
The Evolving Role of Immunotherapy***

**Chair:**

D. Hoelzer, Frankfurt, DE

**M. Subklewe, Munich, DE**

*BiTing Leukemia: CD33/CD3 Bispecific Antibody Constructs  
for the Treatment of AML  
Treatment in AML*

**N. Gökbuget, Frankfurt, DE**

*CD-19 BiTE®: A New Strategy for Hematologic Malignancies*

**20.00-22.00 SOCIAL PROGRAM**

**Welcoming Reception at LeMeridien**

(Hotel LeMERIDIEN, Bayerstraße 4, D-80335 Munich)

**Since space is limited official registration either advance ([www.acute-leukemias.de](http://www.acute-leukemias.de)) or on-site is obligatory**

A Shuttle Bus Service will be available after the end of Satellite II for all participants who have officially registered for ISALXVI and the Welcoming Reception at LeMeridien (Details about bus stop and tickets will be available on site)





---

**M O N D A Y , February 20, 2017**

**08.30-08.45 WELCOME ADDRESS**

**W. Hiddemann, Munich, DE**  
Symposium Chairman

**08.45-10.45 MS III: Genetic and Molecular Characterization of AML:  
Novel Markers for Diagnosis and Prognosis**

*(Lecture Hall III/IV)*

**Co-Chairs:**

H. Serve, Frankfurt, DE  
B. Löwenberg, Rotterdam, NL

**08.45-09.05 J.E. Churpek, Chicago, IL, USA**

*Familial AML Predisposition Syndromes*

**09.05-09.25 R. Bejar, La Jolla, CA, USA**

*Clonal Hematopoiesis, ICUS and MDS: Diagnostic  
Challenges and Clinical Relevance*

**09.25-09.45 J. Byrd, Columbia, OH, USA**

*Beat AML Study of the LLS*

**09.45-10.05 E. Papaemmanuil, New York, NY, USA**

*Personally Tailored Leukemia Management of  
Based on Knowledge Banks of Genomic and  
Clinical Data*

**10.05-10.25 K. Metzeler, Munich, DE**

*Persistence of Driver Mutations during Complete Remission  
Associates with Shorter Survival and Contributes to the Inferior  
Outcomes of Elderly Patients with Acute Myeloid Leukemia*

**10.25-10.45 T. Herold, Munich, DE**

*Prediction of Primary Refractory Acute Myeloid Leukemia*

**10.45-11.15 COFFEE BREAK**

---



---

**M O N D A Y , February 20, 2017**

**11.15-12.15 THOMAS-BÜCHNER LECTURE**  
*(Lecture Hall III/IV)*

**Introduction**

C. Bloomfield, Columbus, OH, USA

**W. Hiddemann, Munich, DE**

*From Cell Kinetics to Targeted Therapy  
in AML*

**12.00-13.45 LUNCH**

**13.00-13.45 MTPI: Meet-the-Professor Session**  
Industry sponsored Session (p. 51)  
(Lecture Hall V)

***New Drugs – New Risks? Pulmonary Complications during  
Treatment for Hematologic Malignancies***

G. Maschmeyer, Potsdam, DE

---



**MONDAY , February 20, 2017**

**12.45-13.45 SATELLITE SYMPOSIUM III**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***Reinforcing the Efficacy of Immunotherapy for the  
Maintenance of remission in AML with Ceplene***

**Chair:**

W. Hiddemann, Munich, DE

**Opening Remarks:**

W. Hiddemann, Munich, DE

**12.50-13.10** K. Hellstrand, Gothenburg, SE  
Role of Cytotoxic T Cells in Remission Maintenance with  
Ceplene/IL-2 Therapy in AML

**13.10-13.15** Discussion

**13.15-13.40** Rowe, J., Jerusalem, IL  
Maintenance Therapy in AML

**13.40-13.45** Discussion



---

**M O N D A Y , February 20, 2017**

**13.45-15.45 MS IV: Novel Approaches and Targeted Therapies in AML**

*(Lecture Hall III/IV)*

**Co-Chairs:**

I. Jeremias, Munich, DE

H. Dombret, Paris, F

**13.45-14.05 E.H. Estey, Seattle, WA, USA**  
*Endpoints for New Drug Approvals in AML*

**14.05-14.25 M. Konopleva, Houston, TX, USA**  
*Targeted Agents in AML (ABT199)*

**14.25-14.45 R.M. Stone, Boston, MA, USA**  
*FLT3-Inhibition in FLT3 Mutated AML*

**14.45-15.05 M.J. Levis, Baltimore, MD, USA**  
*A Perspective on FLT3 Inhibitor Trials Results*

**15.05-15.25 M.S. Tallman, New York, NY, USA**  
*Targeting IDH Mutations in AML*

**15.25-15.45 G.J. Roboz, New York, NY, USA**  
*Bromodomain Inhibition in AML*

**15.45-17.00 MS V: Poster Discussion Session (Posters s. pp 29-44)**

**(Posters** will be presented on the **Upper Floor** of the symposium venue. A cheese and wine tasting is organized, where a great variety of Bavarian cheese will be served).

**All poster** presenters are expected to participate in **MS V** to allow all participants and members of the jury to talk to the presenters and have a personal scientific exchange about their poster(s).

---



**M O N D A Y , February 20, 2017**

**16.30-18.00 SATELLITE SYMPOSIUM IV**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***Diagnosis and Management of APL: Teva Young Hematologists Award***

**Co-Chairs:**

P. Fenaux, Bobigny, F  
R.F. Schlenk, Heidelberg, DE

**16:30–16:35 Welcome and Introduction**  
*Chair: Pierre Fenaux, France*

**16:35–16:50 APL: From Worst Prognosis to Best Outcome**  
*Pierre Fenaux, France*

**16:50–17:05 Best Abstract Presentation 1**  
(Includes 3 minutes for Q&A)

**17:05–17:20 Best Abstract Presentation 2**  
(Includes 3 minutes for Q&A)

**17:20–17:35 Best Abstract Presentation 3**  
(Includes 3 minutes for Q&A)

**17:35–17:50 Best Abstract Presentation 4**  
(Includes 3 minutes for Q&A)

**17:50–18:00 Conclusions**  
*Chair: Richard Schlenk, Germany*



**MONDAY , February 20, 2017**

**18.15-19.15 SATELLITE SYMPOSIUM V**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***Raising the Bar in AML: Novel Endpoints and  
New Treatment Approaches***

**Chair:** W. Hiddemann, Munich, DE

**Learning Objectives:**

After participating on this Symposium you should be able to:

- Explain the Importance of MRD Assessment in AML Clinical Trials in improving Patient Outcomes
- Describe the Main Immunotherapy Targets in AML and the Rationale for the Use of these Agents

**18.15 Introduction**

W. Hiddemann, Munich, DE

**18.25 G. Ossenkoppele, Amsterdam, NL**

*Utility of MRD Assessment in AML*

**18.40 Panel Discussion**

**18.55 G. Roboz, New York, NY, USA**

*Future Treatment Options for Patients with AML: A Focus on Immunotherapy*

**19.05 Panel Discussion**

The **Scientific Program** will end at **19.15**. The remainder of the day stands at free disposal, allowing all participants to make their own arrangements for the evening.



---

**T U E S D A Y**, February 21, 2017

**08.30-10.30 MS VI: Risk Adapted Therapy of AML**

*(Lecture Hall III/IV)*

**Co-Chairs:**

R.P. Gale, Los Angeles, CA, USA

M.S. Tallman, New York, NY, USA

**08.30-08.50 C.D. Bloomfield, Columbus, OH, USA**

*ELN Guidelines: Important Changes*

**08.50-09.10 H. Döhner, Ulm, DE**

*AML-SG Trials*

**09.10-09.30 K. Spiekermann, Munich, DE**

*AML-CG Data*

**09.30-09.50 N.G. Russell, Nottingham, UK**

*Risk Adapted Therapy of AMNL in MRC/NCRI Trials*

**09.50-10.10 R.E. Champlin, Houston, TX, USA**

*Who should receive a Transplant in CR1?*

**10.10-10.30 M. Bornhäuser, Dresden, DE**

*Concepts of the SAL*

**10.30-10.50 COFFEE BREAK**

---



---

**T U E S D A Y**, February 21, 2017

**10.50-12.30 MS VII: Biology and Treatment of APL**  
*(Lecture Hall III/IV)*

**Co-Chairs:**

P. Fenaux, Bobigny, F  
W.-K. Hofmann, Mannheim, DE

**10.50-11.10 H. de Thé, Paris, F**  
*PML, the Unexpected Effector of APL Cure by Retinoic Acid and Arsenic Trioxide*

**11.10-11.30 E. Lengfelder, Mannheim, DE**  
*The AML-CG Trials in APL*

**11.30-11.50 F. Lo Coco, Rome, I**  
*Chemotherapy-Free Treatment in APL*

**11.50-12.10 N.G. Russell, Nottingham, UK**  
*The Feasibility of More Attenuated Dosage Schedules in APL*

**12.10-12.20 P. Montesinos, Valencia, E**  
*Therapy-Related and Secondary APL*

**12.30-14.00 L U N C H**

**13.15-13.45 MTPII: Meet-the-Professor Session**  
Industry sponsored Session (p. 51)  
(Lecture Hall V)

***Midostaurin in AML***  
R.F. Schlenk, Heidelberg, DE

---





---

**T U E S D A Y , February 21, 2017**

**14.00-15.40 MS VIII: Relevance of MRD in Acute Leukemias**  
*(Lecture Hall III/IV)*

**Co-Chairs:**

K.-A. Kreuzer, Cologne, DE

G.J. Schuurhuis, Amsterdam, NL

**14.00-14.20 Ivey, A., Melbourne, AU**  
*Relevance of MRD in Standard Risk AML*

**14.20-14.40 R.B. Walter, Seattle, WA, USA**  
*Using Measurable Residual Disease (MRD) Information  
To Guide Transplant Practice for Acute Leukemia*

**14.40-15.00 S. Freeman, Birmingham, UK**  
*Tracking MRD together with LSC-Enriched Populations  
to Predict Transplant Outcomes in AML*

**15.00-15.20 Th. Köhnke, Munich, DE**  
*Early Detection and Alternative Gating Strategies in  
Flow MRD*

**15.20-15.40 M. Brüggemann, Kiel, DE**  
*Will NGS Improve MRD Evaluation in ALL?*

**15.45-16.15 COFFEE BREAK**

---



**T U E S D A Y , February 21, 2017**

**16.15-17.30 MS IX: Prize Giving Ceremony and Presentation**  
**(Lecture Hall V)**

**Co-Chairs:**

R. Hehlmann, Mannheim, DE

J. Ritter, Münster, DE

**16.15-16.20 Poster Prizes:**  
Official Announcement of this Year's 2 Poster Award Winners

**16.20-16.25 3 Best of Free Contributions:**

**16.25-16.35 *BCL6 is Critical to Overcome Oncogene-Induced Senescence in RAS-Driven Leukemogenesis***

**Linda Chan**, Christian Hurtz, , Gang Xiao, Ari Melnick & Markus Müschen:  
University of California San Francisco, San Francisco CA 94143, USA

**16.35-16.45 *Chemotherapy Resistant Human Acute Myeloid Leukemia Cells are not Necessarily Enriched for Leukemic Stem Cells but Require Oxidative Metabolism***

Jean-Emmanuel Sarry, **Thomas Farge**, Estelle Saland, Fabienne de Toni, Nesrine Aroua, Mohsen Hosseini, Clément Larrue, Héléna Boutzen, François Vergez, and Christian Récher

INSERM, Cancer Res. Ctr of Toulouse, U1037, F-31024 Toulouse, France;  
Univ. of Toulouse, F-31300 Toulouse, France; Dépt. d'Hématologie, Ctr Hospitalier Univ. de Toulouse, Inst. Univ. du Cancer de Toulouse, France;  
Consortium IMODI«Innovative MODElsInitiative against cancer», France

**16.45-16.55 *Deciphering the Oncogenic Network of PRC2 Loss Guided Leukemogenesis***

**D. Schneider**<sup>1</sup>, JH. Klusmann<sup>1\*</sup>, and D. Heckl<sup>1\*</sup>

<sup>1</sup>Pediatric hematology and oncology, Hannover Medical School, Germany;

\*contributed equally

**17.00-17.20 Leukemia Clinical Research Award 2017 (LCRA):**  
Official announcement of the *LCRA 2017* laureate followed by a 15 minutes' presentation

**17.20-17.30 Final Remarks - Prize Giving Ceremony**



**T U E S D A Y , February 21, 2017**

**16.30-17.30 SATELLITE SYMPOSIUM VI**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***Upcoming Frontiers in the Treatment of AML***

**Chair:**

W. Hiddemann, Munich, DE

**Opening:**

W. Hiddemann, Munich, DE

**Groenbaek, K., Copenhagen, DK**

*Modulation of the Immune System by Epigenetic Therapy:  
A Rationale for Combined Use of DNA Methyltransferase  
Inhibitors and Immune Checkpoint Inhibitors*

**Thol, F., Hannover, DE**

*Key Epidemiologic and Clinical Findings in AML Patients  
with IDH Mutations*

**17.30-17.45 Coffee Break**



**T U E S D A Y , February 21, 2017**

**17.45-18.45 SATELLITE SYMPOSIUM VII**

Industry sponsored Satellite (p. 51)  
(Lecture Hall III/IV)

***New Perspectives in AML***

**Chair:**

W. Hiddemann, Munich, DE

**Introduction**

W. Hiddemann, Munich, DE

**U. Krug, Leverkusen, DE**

*How can we Optimize 7+3?*

**H. Kantarjian, Houston, TX, USA**

*How can we Expand 7+3?*

**Summary and Final Discussion**

W. Hiddemann, Munich, DE

**20.00-22.30 Social Evening and Festive Dinner at the Munich Castle**

A Shuttle Bus Service will be available for all participants joining the Social Evening at the Munich Castle "Residenz" after the end of Satellite VII (Details will be announced on site)

**Admission:**

Invited speakers and Chairpersons: Free Access

Regular Participants: € 30,00\*

Physicians-in-training, Students and Nurses: € 20,00\*

\*Tickets can be bought **online** between January 15 and February 18, 2017 at: [www.acute-leukemias.de](http://www.acute-leukemias.de) **or on-site** at the registration desk during the official coffee and lunch breaks from Sunday, February 19 to Tuesday, February 21, 2017.

**Since space is limited advance registration is advisable.**



---

**W E D N E S D A Y** , February 22, 2017

**08.30-10.30 MS X: Immunotherapy for Acute Leukemias**  
*(Lecture Hall III/IV)*

**Co-Chairs:**

G. Ehninger, Dresden, DE

Ch. Peschel, Munich, DE

**08.30-08.50 J. Park, New York, NY, USA**  
*CAR T Cells*

**08.50-09.10 J. DiPersio, St. Louis, MO, USA**  
*T-Cell Recruiting Antibodies*

**09.10-09.30 N. Daver, Houston, TX, USA**  
*Immune Checkpoint Based Approaches in AML/MDS*

**09.30-09.50 M. Subklewe, Munich, DE**  
*DC-Study in AML*

**09.50-10.10 H. Dolstra, Nijmegen, NL**  
*Checkpoint Inhibition in Acute Myeloid Leukemia*

**10.10-10.30 R. Bargou, Würzburg, DE**  
*BITE Antibodies for the Treatment of Acute Leukemias*

**10.30-11.00 COFFEE BREAK**

---



---

**W E D N E S D A Y** , February 22, 2017

**11.00-12.40 MS XI: ALL: Biology and Treatment Strategies**  
*(Lecture Hall III/IV)*

**Co-Chairs:**

D. Hoelzer, Frankfurt a.M., DE  
Ch. A. Schiffer, Detroit, MI, USA

**11.00-11.20 Ch. Mullighan, Memphis, TN, USA**  
*The Evolving Genomic Landscape of Acute Lymphoblastic Leukemia: Subtypes, Genes and Targets*

**11.20-11.40 N. Gökbuget, Frankfurt, DE**  
*Treatment of ALL in Adults*

**11.40-12.00 H. Kantarjian, Houston TX, USA**  
*Can we Cure Ph Positive ALL (without Allogeneic Stem Cell Transplant?)*

**12.00-12.20 M. Schrappe, Kiel, DE**  
*Treatment of ALL in Childhood*

**12.20-12.40 J. Tischer, Munich, DE**  
*Haploidentical Stem Cell Transplantation In ALL*

**12.40-13.00 CLOSING REMARKS**

---



## POSTERS

### Poster Viewing:

Monday, February 20, 2017: 13.00 – 18.00

Tuesday, February 21, 2017: 09.00 – 18.00

### Poster Presentation and Discussion Session:

Monday, February 20, 2017: 15.45 – 17.00 (MSV)

### Prize Giving Ceremony: 3 of Best Free Contributions:

Tuesday, February 21, 2017: 16.15 – 17.30 (MSIX)

## I. LEUKEMIC STEM CELLS

### **(1) RIPK3-Dependent Cell Death and Differentiation of Leukemia Initiating Cells Restrict Myeloid Leukemogenesis**

U. Höckendorf, M. Yabal, P.J. Jost, *et al.*

III. Medical Department for Hematology and Oncology, Klinikum rechts der Isar, Technische Universität München, Germany

### **(2) Temporal but Distinct Requirements of a Transcriptional Repressor Domain for FUNX1/ETO Driven Human CD34+ Progenitor Cell Transformation**

Carolin Preiss<sup>1</sup>, Linping Chen-Wichmann<sup>1</sup>, Marina Shvartsman<sup>1</sup>, Colin Hockings<sup>4</sup>, Georg Leubolt<sup>2</sup>, Enric Redondo-Monte<sup>2</sup>, Christian Brendel<sup>3</sup>, Raymund Buhmann<sup>1</sup>, Philipp A. Greif<sup>2,5,6</sup>, and Christian Wichmann<sup>1</sup>

<sup>1</sup> Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, Ludwig-Maximilian-University, München, Germany; <sup>2</sup> Department of Internal Medicine 3, University Hospital, Ludwig-Maximilian-University, München, Germany; <sup>3</sup> Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; <sup>4</sup> The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia  
<sup>5</sup> German Cancer Consortium (DKTK), Heidelberg, Germany

### **(3) Clinical Outcome of Myeloid Sarcoma in Adult Patients and Effect of Allogeneic Stem Cell Transplantation. Results from a Multicenter Survey.**

D. Lazzarotto (1), A. Candoni (1), C. Fili (1), M.E. Zannier (1), F. Forghieri (2), L. Pagano (3), A. Busca (4), G. Ventura (1), G. Spinosa (5), E. Simeone (1), M. Isola (6), E. Borlenghi (7), M. Criscuolo (3), L. Melillo (8), F. Mosna (9), F. Lessi (10), R. Fanin (1); (1) Hematology and BMT section, University of Udine, Italy. (2) Dpt of Hematology, University of Modena and Reggio Emilia, Italy. (3) Dpt of Hematology, UCSC, Rome, Italy. (4) Dpt of Hematology, Ospedale S. Giovanni Battista, Torino, Italy. (5) Dpt of Hematology, AOU Ospedali Riuniti di Foggia, Italy. (6) Section of Statistics, University of Udine, Italy. (7) Dpt of Hematology, AO Spedali Civili di Brescia, Italy. (8) Dpt of Hematology, IRCCS Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy. (9) Dpt of Hematology, Ospedale Ca' Foncello, Treviso, Italy

### **(4) Mapping the Lncrna-Landscape of Human Hematopoiesis and Leukemia Reveals Stem Cell Non-Coding Gene Expression Programs**

Adrian Schwarzer<sup>1,\*</sup>, Stephan Emmrich<sup>1,\*</sup>, Dominik Beck<sup>2</sup>, Franziska Schmidt<sup>1</sup>, Michelle Ng<sup>1</sup>, Felix Ferdinand Adams<sup>1</sup>, Damian Witte<sup>1</sup>, Sebastian Käbler<sup>1</sup>, Jason W. H. Wong<sup>2</sup>, Anushi Shah<sup>2</sup>, Razan Jammal<sup>1</sup>, Aliaksandra Maroz<sup>1</sup>, Christina Reimer<sup>1</sup>, John E. Pimanda<sup>2</sup>, Dirk Reinhardt<sup>3</sup>, Dirk Heckl<sup>1</sup>, and Jan-Henning Klusmann<sup>1</sup>; <sup>1</sup> Hannover Medical School, Hannover, Germany, <sup>2</sup> Lowy Cancer Research Centre, UNSW Sydney, Australia, <sup>3</sup> University Hospital Essen, Essen, Germany



**(5) Members of the MIR-99/100~125 Tricistrons Cooperatively Induce a Pre-Leukemic Phenotype**

O. Alejo<sup>1\*</sup>, S. Emmrich<sup>1\*</sup>, M. Flasinski<sup>1</sup>, D. Heckl<sup>1</sup>, JH. Klusmann<sup>1</sup>

<sup>1</sup>Pediatric Hematology and Oncology, Hannover Medical School, Germany; \*contributed equally

**(6) A Rare Population of Drug Resistant, Dormant Stem Cells Exists in Patients' Acute Lymphoblastic Leukemia Growing in Mice**

S. Ebinger<sup>1</sup>, W. Liu<sup>1</sup>, Sebastian Tiedt<sup>1</sup>, Catarina Castro Alves<sup>1</sup>, I. Jeremias<sup>1-3</sup>

<sup>1</sup>Helmholtz Zentrum München, Munich, Germany; <sup>2</sup>German Cancer Consortium (DKTK), Partner site Munich, Germany; <sup>3</sup>Dr. von Haunersches Kinderspital, Ludwig Maximilians University, Munich, Germany

**(7) Significantly Reduced CFU-F Frequency and Increased Adipogenic Differentiation of Mesenchymal Stem Cells (Msc) in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)**

M.-T. Weickert<sup>1</sup>, A.-K. Garz<sup>1</sup>, J. Hecker<sup>1</sup>, C. Ziegenhain<sup>2</sup>, S. Grath<sup>2</sup>, D. Strunk<sup>3</sup>, C. Peschel<sup>1</sup>, W. Enard<sup>2</sup>, R. A. J. Oostendorp<sup>\*1</sup>, K. S. Götze<sup>\*1</sup>

<sup>1</sup> Technische Universität München, III. Medizinische Klinik, München, Germany, <sup>2</sup> Ludwig-Maximilians-University Munich, Department Biology II, Germany; <sup>3</sup> Paracelsus Medical University Salzburg, Research Institute of Experimental and Clinical Cell Therapy, Salzburg, Austria

**(8) The Splicing Factor Binding Protein KIS (UHMK1) Participates in Hematopoietic Cell Differentiation**

I. Barbutti<sup>1</sup>; V. C. Arfelli<sup>2</sup>; J. A. Machado-Neto<sup>3</sup>; J. Xavier-Ferrucio<sup>1</sup>; F. Traina<sup>3</sup>; S. T. O. Saad<sup>1</sup>; L. Fröhlich-Archangelo<sup>1,2</sup>

<sup>1</sup>Hematology and Hemotherapy Center, State University of Campinas-UNICAMP, Campinas, and INCT Sangue, Brazil; <sup>2</sup> Department of Cellular and Molecular Biology and Pathogenic Bioagents, XIV MUC, Ribeirão Preto, São Paulo, Brazil; <sup>3</sup> Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

## II. AML – BIOLOGY

**(9) Circular *NPM1* RNAS in Acute Myeloid Leukemia**

S. Hirsch<sup>1</sup>, T.J. Blätte<sup>1</sup>, S. Grasedieck<sup>1</sup>, A. Rouhi<sup>1</sup>, M. Jongen-Lavrencic<sup>2</sup>, F. Kuchenbauer<sup>1</sup>, P. Paschka<sup>1</sup>, V.I. Gaidzik<sup>1</sup>, K. Döhner<sup>1</sup>, S. Cocciardi<sup>1</sup>, A. Dolnik<sup>1</sup>, L. Bullinger<sup>1</sup>

<sup>1</sup>Department of Internal Medicine III, University Hospital of Ulm, Germany; <sup>2</sup>Erasmus University Medical Center, Rotterdam, The Netherlands

**(10) SHIP1 Suppresses Proliferation of Leukemic Cells *IN VIVO***

M. Täger<sup>1</sup>, J.Wellbrock<sup>2</sup>, E. Latuske<sup>2</sup>, P. Ehm<sup>1</sup>, M. Nalaskowski<sup>1</sup>, M. Jücker<sup>1</sup>

<sup>1</sup>UKE, Center for Experimental Medicine, Institute of Biochemistry and Signal Transduction - Hamburg, Germany; <sup>2</sup>UKE, Department of Oncology, Haematology and Bone Marrow Transplantation with section Pneumology, Hubertus Wald University Cancer Center - Hamburg, Germany





**(11) Epigenetic Drug Treatment Globally Induces Cryptic Transcription Start Sites Encoded in Long Terminal Repeats**

M. Daskalakis<sup>1</sup>, D. Brocks<sup>1</sup>, C. Schmidt<sup>2</sup>, D. Li<sup>3</sup>, J. Li<sup>3</sup>, H.S. Jang<sup>3</sup>, B. Zhang<sup>4</sup>, D. Lipka<sup>1</sup>, J. Schott<sup>5</sup>, H. Bierhoff<sup>6</sup>, Y. Assenov<sup>1</sup>, M. Helf<sup>1</sup>, A. Ressenrova<sup>1</sup>, A. Lindroth<sup>7</sup>, S. Haas<sup>8</sup>, M.A.G. Essers<sup>8</sup>, C.D. Imbusch<sup>9</sup>, B. Brors<sup>9</sup>, I. Oehme<sup>10</sup>, O. Witt<sup>10</sup>, M. Lübbert<sup>11</sup>, G. Stoecklin<sup>5</sup>, C. Gerhäuser<sup>1</sup>, C.C. Oakes<sup>12</sup>, T. Wang<sup>3</sup> and C. Class<sup>1</sup>

<sup>1</sup>Div. of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>2</sup>Merck KGaA, Darmstadt, Germany; <sup>3</sup>Dept. of Genetics, Center for Genome Sciences and Systems Biology, Washington Univ. School of Medicine, St. Louis, MO; <sup>4</sup>Dept. of Developmental Biology, Washington Univ., St. Louis, MO; <sup>5</sup>Center for Molecular Biology of Heidelberg Univ., Germany; <sup>6</sup>Dept. of Genetics, Friedrich Schiller Univ. Jena, Germany; <sup>7</sup>Graduate School of Cancer Science and Policy National Cancer Center, Goyang-si, Korea, The Republic of; <sup>8</sup>(1) Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), and (2) Hematopoietic stem cells and stress group, Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>9</sup>(1) Div. Applied Bioinformatics, DKFZ and National Center for Tumor Diseases (NCT), and (2) German Cancer Consortium (DKTK), Heidelberg, Germany; <sup>10</sup>Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and Dept. of Pediatric Oncology, Univ. Hospital, Heidelberg, Germany; <sup>11</sup>Dept. of Medicine I, Medical Center – Univ. of Freiburg, Germany; <sup>12</sup>Div. of Hematology, Dept. of Internal Medicine, Ohio State Univ., Columbus, OH, USA

**(12) MYC-Containing Double Minute Chromosomes: Origin, Structure And Impact Upon Transcriptome In Acute Myeloid Leukemia Patients**

A. L'Abbate<sup>1</sup>, D. Tolomeo<sup>1</sup>, A. Turchiano<sup>1</sup>, M. Pafundi<sup>1</sup>, P. D'Addabbo<sup>1</sup>, M. Carella<sup>2</sup>, O. Palumbo<sup>2</sup>, G. Merla<sup>2</sup>, B. Augello<sup>2</sup>, A. Dolnik<sup>3</sup>, D. Muhlematter<sup>4</sup>, N. Van Roy<sup>5</sup>, C. Haferlach<sup>6</sup>, L. Bullinger<sup>3</sup>, C.T. Storlazzi<sup>1</sup>

<sup>1</sup>Department of Biology, University of Bari "Aldo Moro", Bari, Italy; <sup>2</sup>Laboratory of Oncology, IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy; <sup>3</sup>Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; <sup>4</sup>Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; <sup>5</sup>Center for Medical Genetics, Ghent University, Ghent, Belgium; <sup>6</sup>MLL Munich Leukemia Laboratory, Munich, Germany.

**(13) Clonal Evolution Patterns Differ in AML with *NPM1*<sup>mut</sup>**

S. Cocciardi<sup>1</sup>, S. Kapp-Schwoerer<sup>1</sup>, A. Dolnik<sup>1</sup>, F.G. Rücker<sup>1</sup>, S. Hirsch<sup>1</sup>, T.J. Blätte<sup>1</sup>, S. Skambraks<sup>1</sup>, J. Krönke<sup>1</sup>, A. Corbacioglu<sup>1</sup>, V.I. Gaidzik<sup>1</sup>, P. Paschka<sup>1</sup>, V. Teleanu<sup>1</sup>, G. Göhring<sup>3</sup>, F. Thol<sup>4</sup>, M. Heuser<sup>4</sup>, A. Ganser<sup>4</sup>, E. Sträng<sup>5</sup>, R.F. Schlenk<sup>1</sup>, H. Döhner<sup>1</sup>, L. Bullinger<sup>1\*</sup>, K. Döhner<sup>1\*</sup>

<sup>1</sup>Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

<sup>3</sup>Institute of Cell & Molecular Pathology, Hannover Medical School, Hannover, Germany

<sup>4</sup>Department of Haematology, Haemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

<sup>5</sup>Institute of Medical Systems Biology, Ulm University, 89081 Ulm, Germany

\* these authors contributed equally

**(14) Evolutionary Patterns of Cytogenetically Normal Acute Myeloid Leukemia Correlate with Time to Relapse**

S. Vosberg<sup>1-3</sup>, L. Hartmann<sup>1-3</sup>, K. H. Metzeler<sup>1-3</sup>, D. Schumacher<sup>1</sup>, F. Pastore<sup>1-3</sup>, K. Brändli<sup>1-3</sup>, E. Zellmeier<sup>1</sup>, B. Ksienzyk<sup>1</sup>, N. P. Konstantin<sup>1</sup>, S. Schneider<sup>1</sup>, A. Graf<sup>4</sup>, S. Krebs<sup>4</sup>, H. Blum<sup>4</sup>, M. Neumann<sup>2,3,5</sup>, C. D. Baldus<sup>2,3,5</sup>, S. K. Bohlander<sup>6</sup>, S. Wolf<sup>3</sup>, W. Hiddemann<sup>1-3</sup>, K. Spiekermann<sup>1-3</sup> and P.A. Greif<sup>1-3</sup>

(1) Dept of Internal Medicine 3, University Hospital LMU Munich, Germany; (2) German Cancer Consortium (DKTK), Heidelberg, Germany; (3) German Cancer Research Center (DKFZ), Heidelberg, Germany; (4) LaFuGa, Gene Center, LMU Munich, Germany; (5) Dept of Hematology & Oncology, Charité, Berlin, Germany; (6) Molecular Medicine & Pathology, The University of Auckland, New Zealand



**(15) Inhibition of the Phosphatase STS1 in FLT3-ITD-Positive AML**

J. Zhang<sup>1</sup>, O. Vakhrusheva<sup>1</sup>, M. Thoelken<sup>1</sup>, C. Brandts<sup>1,2</sup>

<sup>1</sup>Department of Medicine, Translational Oncology; <sup>2</sup>University Cancer Center (UCT) Frankfurt; Goethe University, Frankfurt, Germany

**(16) Loss of the Selective Autophagy Receptor P62 Delays Leukemia Development and Impairs Mitophagy**

T.D. Nguyen<sup>1</sup>, S. Shaid<sup>1</sup> and C. Brandts<sup>1,2</sup>; <sup>1</sup>Department of Medicine, Translational Oncology, <sup>2</sup>University Cancer Center (UCT) Frankfurt, Goethe University, Frankfurt, Germany

**(17) TRIB3 Promotes APL Development By Stabilization of PML-RAR $\alpha$**

F. Wang<sup>1\*</sup>, K. Li<sup>2\*</sup>, F. Hua<sup>1</sup> and Z.W. Hu<sup>1</sup> #

<sup>1</sup>Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica; <sup>2</sup>Institute of Medicinal Biotechnology; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, P.R. China

**(18) BCR-ABL+ AML: A New Provisional Entity In The 2016 Revised WHO Classification of Myeloid Malignancies**

N. R. Neuendorff, J. Ihlow, T. Burmeister, B. Dörken, J. Westermann

Dept. of Hematology/Oncology, CVK, Charité University Medicine Berlin, Germany

**(19) Long Non-Coding RNAs Associated with Myeloid Differentiation**

K. Mintzas, I. Hamwi, A. Kloos, J. Krauter, M. Lübbert, L. Kanz, W. Fiedler, G. Heil, P. Paschka, R. F. Schlenk, K. Döhner, H. Döhner, A. Ganser, F. Thol, and M. Heuser

Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany

**(20) Detection of Single-Nucleotide Variants In Acute Myeloid Leukemia (AML) from Bulk and Single-Cell RNA Sequencing**

I. A. Valtierra-Gutiérrez<sup>1,2</sup>, A. Farré-Orteu<sup>1</sup>, M. Richter<sup>1</sup>, P. A. Greif<sup>2,3,4,5</sup>, C. Ziegenhain<sup>1,2</sup>, I. Jeremias<sup>2,4,5,6,7</sup>, K. Metzeler<sup>2,3,4,5</sup>, K. Spiekermann<sup>2,3,4,5</sup>, W. Enard<sup>1,2</sup>, and I. Hellmann<sup>1,2</sup>

[1] Anthropology and Human Genomics, Department Biology II, Faculty of Biology, Ludwig-Maximilians University Munich, Großhaderner Straße 2, 82152 Martinsried, Germany; [2] Collaborative Research Center SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms. Munich, Germany

[3] Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-University Munich, Germany; [4] German Cancer Research Center (DKFZ), Heidelberg, Germany

[5] German Cancer Consortium (DKTK), Heidelberg, Germany; [6] Helmholtz Zentrum München, Marchioninistr. 25, 81377 Munich, Germany; [7] Dr. von Haunersches Kinderspital, Ludwig-Maximilians University Munich, Lindwurmstraße 4, 80337 Munich, Germany

**(21) Transcriptomic Classification of AML**

T.J. Blätte, A. Dolnik, L. Bullinger

Dept. of Internal Medicine III, University Hospital of Ulm, Germany

**(22) Functional Characterization of the H3K27 Demethylase KDM6A in Acute Myeloid Leukemia**

S. Janich<sup>1-3</sup> / L. Hartmann<sup>1-3</sup> / S. Vosberg<sup>1-3</sup> / R. Mattes<sup>1</sup> / H. Polzer<sup>1-3</sup> / H. Leonhardt<sup>4</sup> / P. Greif<sup>1-3</sup> / W. Hiddemann<sup>1-3</sup> / K. Spiekermann<sup>1-3</sup>

<sup>1</sup>Internal Medicine III, Hospital Grosshadern, Ludwig Maximilians University (LMU), Munich, Germany;

<sup>2</sup>German Cancer Consortium (DKTK), Munich, Germany; <sup>3</sup>German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>4</sup>Department of Bioluminescence, Ludwig Maximilians University (LMU), Munich, Germany



**(23) ASXL1 Mutations in AML are Associated Mainly with s-AML and Specific Cytogenetic Findings**

K. Kakosaiou<sup>1</sup>, M. Pagoni<sup>2</sup>, A. Daraki<sup>1</sup>, P. Apostolou<sup>3</sup>, A. Ioannidou<sup>1</sup>, S. Zachaki<sup>1</sup>, I. Vlachadami<sup>4</sup>, T. Marinakis<sup>5</sup>, C. Giatra<sup>2</sup>, D. Vasilatou<sup>6</sup>, C. Sambani<sup>1</sup>, V. Pappa<sup>6</sup>, K. N. Manola<sup>1</sup>  
<sup>1</sup>Lab of Health Physics, Radiobiology & Cytogenetics, NCSR "Demokritos", Athens, Greece; <sup>2</sup>Hematology-Lymphoma Dept - BMT Unit, Evangelismos Hospital, Athens, Greece; <sup>3</sup>Lab of Molecular Diagnostics, NCSR "Demokritos", Athens, Greece; <sup>4</sup>Dept. of Pathophysiology, 'Laiko' Hospital, University of Athens, Greece; <sup>5</sup>Department of Haematology, "Georgios Gennimatas" General Hospital, Athens, Greece; <sup>6</sup>Hematology Unit, University General Hospital "Attikon", Athens, Greece

**(24) Comparative Analysis of Single-Cell - RNA Sequencing Methods**

C. Ziegenhain, B. Vieth, S. Parekh, B. Reinius, A. Guillaumet-Adkins, M. Smets, H. Leonhardt, H. Heyn, I. Hellmann, W. Enard  
Anthropology & Human Genomics, Department Biology II, Ludwig-Maximilians University Munich, Germany

**(25) MUTATIONAL Analysis of 206 DE NOVO AML Patients below 60 Years with Curative Therapy in Czech Republic**

A. Foltá<sup>1</sup>, I. Jezisková<sup>1</sup>, D. Dvorakova<sup>1,2</sup>, N. Tom<sup>2</sup>, M. Culen<sup>1,2</sup>, Z. Kosarova<sup>2</sup>, A. Durinikova<sup>2</sup>, P. Cetkovsky<sup>3</sup>, P. Jindra<sup>4</sup>, T. Szotkowski<sup>5</sup>, P. Zak<sup>6</sup> and Z. Racil<sup>1,2</sup>  
<sup>1</sup> University Hospital Brno, Brno, CZ; <sup>2</sup> Masaryk University, Brno, CZ; <sup>3</sup> Institute of Hematology and Blood Transfusion, Prague, CZ; <sup>4</sup> University Hospital Pilsen, Pilsen, CZ; <sup>5</sup> University Hospital Olomouc, Olomouc, CZ; <sup>6</sup> University Hospital Hradec Kralove, Hradec Kralove, CZ; on behalf of CELL

**(26) Transcriptional Heterogeneity in AML - Evolution of Gene Expression in Patient Derived Xenografts**

Johannes Bagnoli<sup>1,2</sup>, C. Ziegenhain<sup>1,2</sup>, B. Vieth<sup>1,2</sup>, S. Parekh<sup>1,2</sup>, B.Vick<sup>2,3,4,5</sup>, I. Jeremias<sup>2,3,4,5,6</sup>, I. Hellmann<sup>1,2</sup> and W. Enard<sup>1,2</sup>  
[1] Anthropology and Human Genomics, Department Biology II, Faculty of Biology, Ludwig-Maximilians University Munich, Großhaderner Straße 2, 82152 Martinsried, Germany; [2] Collaborative Research Center SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms. Munich, Germany; [3] German Cancer Research Center (DKFZ), Heidelberg, Germany; [4] German Cancer Consortium (DKTK), Heidelberg, Germany; [5] Helmholtz Zentrum München, Marchioninstr. 25, 81377 Munich, Germany; [6] Dr. von Haunersches Kinderspital, Ludwig-Maximilians University Munich, Lindwurmstraße 4, 80337 Munich, Germany.

**(27) Age Dependent Limit for Erythroid Dysplasia of 25-30 % in Acute Myeloid Leukemia with Myelodyspoasia-Related Changes**

P. Lemez<sup>1,2</sup>, J. Galikova<sup>2</sup>, K. Michalova<sup>3</sup>, A. MacWhannell<sup>1</sup>, Z. Zemanova<sup>3</sup>, T. Haas<sup>4</sup>, J. Stejskal<sup>2</sup>  
<sup>1</sup>Dept. Hematol., New Cross Hosp., Wolverhampton, England, <sup>2</sup>Dept. Hematol., Hosp. Jihlava, Jihlava, <sup>3</sup>Centre of Oncocytogenetics, 1st Med. Fac., Charles Univ., Prague, Czech Republic, <sup>4</sup>Novartis Oncology, Basel, Switzerland

**(28) Clinical and Germline Genetic Study on a Consecutive Series of Acute Myeloid Leukemias in Finland 2015-2016**

U. Wartiovaara-Kautto<sup>1</sup>, E. A. M. Hirvonen<sup>3</sup>, C. Heckman<sup>2</sup>, J. Saarela<sup>2</sup>, K. Kettunen<sup>2</sup>, K. Porkka<sup>1</sup>, O. Kilpivaara<sup>3</sup>. 1 Dept of Hematology, Helsinki University Hospital (HUH) Comprehensive Cancer Center, Helsinki, 2 Institute for Molecular Medicine Finland, University of Helsinki, 3 Genome-Scale Biology, Research Programs Unit, University of Helsinki, Finland



**(29) Evaluation of Terra Expression Levels and its Correlation with Telomere Length and hTERT Expression in Patients with Acute Myeloid Leukemia**

L.C Zanelatto<sup>a</sup>, J.P.L Silva<sup>a</sup>, B.A Santana-Lemos<sup>a</sup>, R.T Calado<sup>a</sup>

<sup>a</sup>Laboratory of Hematology, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil

**(30) Characterization of Spliceosome Mutations in Patients with Acute Myeloid Leukemia**

S. A. Bamopoulos<sup>1</sup>, A. M. N. Batcha<sup>24</sup>, V. Jurinovic<sup>4</sup>, K. H. Metzeler<sup>1-3</sup>, M. Rothenberg- Thurley<sup>1</sup>, B. Ksienzyk<sup>1</sup>, L. Hartmann<sup>1-3</sup>, P.A. Greif<sup>-3</sup>, J. Phillippou-Massier<sup>5</sup>, S. Krebs<sup>5</sup>, H. Blum<sup>5</sup>, S. Amler<sup>6</sup>, S. Schneider<sup>1</sup>, N. Konstandin<sup>1</sup>, M. C. Sauerland<sup>6</sup>, W. E. Berdel<sup>7</sup>, B. J. Woermann<sup>8</sup>, S. K. Bohlander<sup>9</sup>, J. Braess<sup>10</sup>, W. Hiddemann<sup>1-3</sup>, U. Mansmann<sup>24</sup>, K. Spiekermann<sup>1-3</sup>, and T. Herold<sup>1-3</sup>

<sup>1</sup>Department of Internal Medicine III, University of Munich, Munich, Germany; <sup>2</sup>German Cancer Consortium (DKTK), Heidelberg, Germany; <sup>3</sup>German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>4</sup>Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany; <sup>5</sup>Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-Universität (LMU) München, München, Germany; <sup>6</sup>Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany; <sup>7</sup>Department of Medicine A-Hematology, Oncology and Pneumology, University at Münster, Münster, Germany; <sup>8</sup>Department of Medicine, Hematology, Oncology, Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; <sup>9</sup>Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand; <sup>10</sup>Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany

**(31) Functional Characterization Of The Impact Of FLT3 Receptor Domains On Cell Signaling**

H. Polzer, W. Hiddemann, and K. Spiekermann

Department of Internal Medicine III, Ludwigs Maximilians University, Munich, Germany

German Cancer Consortium (DKTK), Heidelberg, Germany

German Cancer Research Center (DKFZ), Heidelberg, Germany

**(32) Studying Clonal Dynamics in Cytogenetically Normal AML through Sensitive Backtracking of Relapse-Associated Mutations**

D. Richter, A. Bartels, K. Metzeler, W. Enard

Department Biology II, Ludwig-Maximilians University, Munich, Germany

Medizinische Klinik und Poliklinik III, Ludwig-Maximilians University, Munich, Germany

**(33) Simulation of AML Clonality in NOD SCID GAMMA Mouse**

Z. Kosarova<sup>1</sup>, M. Culen<sup>1,2</sup>, I. Jeziskova<sup>2</sup>, A. Folta<sup>2</sup>, J. Chovancova<sup>1,2</sup>, T. Loja<sup>3</sup>, N. Tom<sup>1,3</sup>, D. Dvorakova<sup>2</sup>, Z. Sustkova<sup>2</sup>, L. Semerad<sup>2</sup> and Z. Ráčil<sup>1,2,3</sup>

<sup>1</sup>Faculty of Medicine, Masaryk University, Brno, <sup>2</sup>University Hospital Brno, <sup>3</sup> CEITEC, Masaryk University, Brno, Czech Republic

**III. AML – THERAPY**

**(34) In-Silico Comparison of Two Induction Regimens (7+3 Vs 7+3 + Additional Evaluation) in Acute Myeloid Leukemia**

J. Banck<sup>1</sup>, D. Görlich<sup>1</sup>

<sup>1</sup>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany



**(35) Comparison of FLT3-ITD Detection of High-Throughput Amplicon Sequencing to Routine Diagnostics – A Retrospective Analysis of AMLCG Study Patients**

K. Reiter<sup>1,2</sup>, M. Hubmann<sup>1</sup>, E. Harin<sup>1</sup>, S. Vosberg<sup>1,2</sup>, K. Brändl<sup>1,2</sup>, B. Ksienzyk<sup>1</sup>, S. Schneider<sup>1</sup>, A. Dufour<sup>1</sup>, E. Zellmeier<sup>1</sup>, S. K. Bohlander<sup>3</sup>, C. Sauerland<sup>4</sup>, W. E. Berdel<sup>5</sup>, B. Wörmann<sup>6</sup>, T. Büchner<sup>5</sup>, J. Braess<sup>7</sup>, W. Hiddemann<sup>1,2</sup>, K. Spiekermann<sup>1,2</sup>, P. A. Greif<sup>1,2</sup>

1.Internal Medicine 3, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany. 2.German Cancer Consortium (DKTK), Munich, Germany. 3.Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand. 4.Biostatistics and Clinical Research, University of Muenster, Muenster, Germany. 5.Medicine A – Hematology and Oncology, University Hospital of Muenster, Muenster, Germany. 6.German Society of Hematology and Oncology, Berlin, Germany. 7.Hematology and Oncology, Barmherzige Brüder Hospital, Regensburg, Germany.

**(36) Performance and Toxicity of FLAI (Fludarabine, Cytarabine, Idarubicin) as Induction Chemotherapy for High Risk Secondary Acute Myeloid Leukemia Arising from Philadelphia-Negative Chronic Myelo Proliferative Neoplasms or Myelodysplastic Syndromes.**

M.E. Zannier, A. Candoni, E. Simeone, D., Lazzarotto, G. Ventura, F. Zanini, C. Fili, C. D'Odorico, C. Comuzzi, R. Fanin

Dept of Hematology and SCT, University Hospital of Udine, Italy

**(37) DNMT3A Mutations Are not a Reliable Marker of MRD in AML**

V. Alfonso<sup>1</sup>, L. Iaccarino<sup>1</sup>, T. Ottone<sup>1,2</sup>, L. Maurillo<sup>1</sup>, F. Buccisano<sup>1</sup>, M. Mancini<sup>1</sup>, L. Cicconi<sup>1</sup>, S. Lavorgna<sup>1,2</sup>, A. Venditti<sup>1</sup>, M. Irno Consalvo<sup>1</sup>, DF. Angelini<sup>2</sup>, L. Battistini<sup>2</sup>, MI. Del Principe<sup>1</sup>, MT. Voso<sup>1</sup>, F. Lo-Coco<sup>1,2</sup>.

<sup>1</sup>Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy, <sup>2</sup>Neuroimmunology and Flow Cytometry Units, Fondazione Santa Lucia-I.R.C.C.S., Rome, Italy

**(38) AML Patients Aged ≥75 Years Enrolled into AMLCG Trials: Do Gene Mutations Impact Clinical Outcome in Very Old, Intensively Treated Patients?**

V.V. Prassek<sup>1</sup>, M. Rothenberg-Thurley<sup>1</sup>, T. Herold<sup>1</sup>, S. Amler<sup>2</sup>, M.C. Sauerland<sup>2</sup>, D. Goerlich<sup>2</sup>, H. Janke<sup>1</sup>, S. Schneider<sup>1</sup>, M. Subklewe<sup>1</sup>, U. Krug<sup>3</sup>, A. Faldum<sup>2</sup>, W.E. Berdel<sup>2</sup>, B.Wörmann<sup>4</sup>, T. Büchner<sup>2</sup>, J. Braess<sup>5</sup>, W. Hiddemann<sup>1</sup>, K. Spiekermann<sup>1</sup>, K.H.Metzeler<sup>1</sup>

<sup>1</sup>LMU München, <sup>2</sup>Universität Münster, <sup>3</sup>Klinikum Leverkusen, <sup>4</sup>Charite – Universitäts-medizin Berlin,

<sup>5</sup>Klinikum Barmherzige Brüder Regensburg – all in Germany

**(39) Residual Leukemic Cells Population and Immunophenotyping Shifts after the First Induction Course in DE NOVO Acute Myeloid Leukemia (AML)**

T. Lobanova, N. Kapranov, Y. Davydova, I. Galtseva, V. Troitskaya, E. Parovichnikova  
National Research Center for Hematology, Moscow, Russian Federation

**(40) Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleukocytic Acute Myeloid Leukemia**

P.L. Mouché<sup>\*1,2</sup>, S. Bertoli, M.D; Ph.D<sup>\*1</sup>, M. Picard, M.D<sup>\*1</sup>, E. Bérard, M.D; Ph.D<sup>\*1</sup>, C. Larrue, Ph.D<sup>\*2</sup>, S. Tavitian, M.D<sup>\*1</sup>, F. Vergez, DVM, Ph.D<sup>\*1</sup>, E. Yon<sup>\*1</sup>, J. Ruiz, M.D<sup>\*1</sup>, E. Delabesse, PharmD; Ph.D<sup>\*1</sup>, I. Luquet, M.D<sup>\*1</sup>, L. Linares, Ph.D<sup>\*3</sup>, M. Carroll, MD<sup>\*4</sup>, A. Sarry<sup>\*1</sup>, F. Huguet, M.D<sup>\*1</sup>, JE. Sarry, Ph.D<sup>\*2</sup> and C. Récher, MD-Ph.D.<sup>1,2</sup>

1Institut Universitaire du Cancer de Toulouse – CHU, France; 2Centre de Recherches en Cancérologie de Toulouse, France; 3Institut de Recherche en Cancérologie de Montpellier, France; 4Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; USA



**(41) Mathematical Analysis And Modelling of Disease Dynamics in NPM1+ AML Using Time Course Data From Clinical Trials**

H. Hoffmann<sup>1</sup>, C. Thiede<sup>2</sup>, M. Bornhäuser<sup>2</sup>, I. Glauche<sup>1</sup>, M. Kramer<sup>2</sup>, C. Röllig<sup>2</sup>, G. Ehninger<sup>2</sup>, I. Roeder<sup>1</sup>  
<sup>1</sup>Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TU Dresden, Germany; <sup>2</sup>Medizinische Klinik und Poliklinik I, Faculty of Medicine Carl Gustav Carus, TU Dresden, Germany

**(42) CD25 Expression as a Risk Factor in Patients with Acute Myeloid Leukemia**

I. Iskrou, A. Uss, and I. Lenzina  
Republic Center of Hematology and Bone Marrow Transplantation, Minsk, Belarus

**(43) A Population-Based Study on First AML Relapse in Sweden**

R. Olsson<sup>1</sup>, M. Höglund<sup>1</sup>, G. Juliusson<sup>2</sup> on behalf of the Swedish AML Group  
<sup>1</sup>Dept. Of Medical Sciences, Unit of Haematology, Uppsala, Uppsala University, Sweden; <sup>2</sup>Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden

**(44) Droplet Digital PCR is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukaemia**

C. Brunetti, L. Anelli, A. Zagaria, A. Minervini, P. Casieri, C. F. Minervini, P. Orsini, C. Cumbo, L. Impera, N. Coccaro, G. Tota, G. Specchia and F. Albano  
Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology Section - University of Bari - 70124 - Bari, Italy

**(45) The Combination of Fludarabine + Citarabine + Idarubicin (FLAI) is a Safe and Effective Treatment for Elderly Patients with AML or High Risk MDS**

E. Crisà, E. Audisio, M. Cerrano, S. D'Ardia, B. Allione, B. Nicolino, S. Aydin, C. Aguzzi, B. Bruno, M. Boccadoro and D. Ferrero  
Hematology Division 1 and 2 , A.O.U. Citta della Salute e della Scienza di Torino, Italy

**(46) Monitoring of Minimal Residual Disease of Mutations in CEBPA Gene in AML Patients Using High Sensitive NGS Technology**

K. Hrochova<sup>1</sup>, F. Vrbacký<sup>2</sup>, L. Petrova<sup>1</sup>, M. Chmelarova<sup>1</sup>, A. Zavrelva<sup>2</sup>, M. Lanska<sup>2</sup>, J. Radocha<sup>2</sup>, P. Žák<sup>2</sup>  
<sup>1</sup>Institute of clinical biochemistry and diagnostics, University Hospital, Hradec Kralove, Czech Republic  
<sup>2</sup> 4th Department of Internal Medicine, Hematology , University Hospital, Hradec Kralove, Czech Republic

**(47) Evaluation of Minimal Residual Disease in NPM1-Mutated AML Patients**

C. Martínez-Laperche<sup>1,2</sup>, G. Rodríguez Macías<sup>1</sup>, V. Pradillo<sup>1</sup> M. Bastos<sup>1,2</sup>, J. Suarez<sup>1,2</sup>, M. Chicano<sup>1,2</sup>, D. Carbonel<sup>1,2</sup>, JL Diez-Martín<sup>1,2</sup>, I. Buño<sup>1,2</sup> Servicio de Hematología y Hemoterapia. Hospital General Universitario Gregorio Marañón, Madrid, España. <sup>2</sup> Instituto de Investigación Sanitaria. Hospital General Universitario Gregorio Marañón, Madrid, España

**(48) Aberrant NCAM Expression as a Therapeutic Target in AML**

D.Sasca<sup>1</sup>, A. Schüller<sup>1</sup>, J. Szybinski<sup>1</sup>, O. Kriege<sup>1</sup>, P. Haehnel<sup>1</sup>, J. Heidelberger<sup>2</sup>, A. Dolnik<sup>3</sup>, W.H. Gebhardt<sup>2</sup>, G. Reid<sup>2</sup>, M.Theobald<sup>1</sup>, P. Belí<sup>2</sup>, L.Bullinger<sup>3</sup>, and T. Kindler<sup>1</sup>  
<sup>1</sup>Department of Hematology, Medical Oncology & Pneumology, University Medical Center of Mainz,  
<sup>2</sup>Institute of Molecular Biology, Mainz, <sup>3</sup>Department of Internal Medicine III, University Hospital of Ulm, all Germany



**(49) Therapeutic Targeting of GLI-Code in AML**

S. Al-Harbi, M. Hasipek, J. G. Phillips J. P. Maciejewski and B. K. Jha,  
Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA

**(50) WT1 on days 14 and 28 Predicts DFS in AML Patients with Both the Isolated NPM1 Mutation and NPM1 Mutation with Additional Molecular Markers**

L. Girshova, I. Budaeva, S. Kuzin, E. Ovsiannikova, K. Bogdanov, T. Nikulina, J. Mirolubova, D. Motorin, and A. Zaritskey.  
Federal Almazov North-West Medical Research Centre, Saint Petersburg, Russia

**(51) Modeling AML Standard Induction Chemotherapy in the PDX Mouse Model**

B. Vick<sup>1,2</sup>, LM Holdt<sup>3</sup>, W Hiddemann<sup>2,4</sup>, K Spiekermann<sup>2,4</sup>, and I Jeremias<sup>1,2,5</sup>  
<sup>1</sup>Department of Gene Vectors, Helmholtz Zentrum München; <sup>2</sup>German Cancer Consortium (DKTK), Partner Site Munich, Germany; <sup>3</sup>Institute of Laboratory Medicine, LMU München; <sup>4</sup>Department of Internal Medicine III, LMU München; <sup>5</sup>Dr von Haunersches Kinderspital, LMU München; all Germany

**(52) A Phase 1b Study of Vadastuximab Talirine (33A) in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)**

R. Walter,<sup>1</sup> H. Erba,<sup>2</sup> and F. Ravandi<sup>3</sup> on behalf of the SGN33A-002 Team  
<sup>1</sup>Fred Hutchinson Cancer Research Center, <sup>2</sup>University of Alabama-Birmingham, USA, <sup>3</sup>MD Anderson Cancer Center, USA

**IV. ALL – BIOLOGY**

**(53) Evaluation of The Specific Interaction Between AF15Q14/CASC5 and FLJ37251/PHORBOLIN1 in Screened Human B-Cell Lymphoblast Line-Derived CDNA Library**

K.V. Bogdanov<sup>1,2</sup> and M. Takimoto<sup>2</sup>  
Federal Almazov North-West Medical Research Centre<sup>1</sup>, St. Petersburg, Russian Federation; Institute for Genetic Medicine<sup>2</sup>, Hokkaido University, Sapporo, Japan

**(54) PP2A Redirects Glucolytic Flux to Maintain Redox Balance and Represents a Novel Target in B-ALL**

G. Xiao, Z. Chen, D. Braas, T.G. Graeber, L.N. Chan, H. Geng and M. Mischen  
University of California San Francisco, San Francisco CA 94143, USA

**(55) CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B-Lineage ALL**

Jaewoong Lee, Ari Melnick, Elisabeth Paietta & Markus Mischen  
University of California San Francisco, San Francisco CA 94143, USA

**(56) Metabolic Gatekeeper Function of B-Lymphoid Transcription Factors**

LN Chan, JW Lee, T Ernst, A Hochhaus, TG Graeber & M Mischen  
University of California San Francisco, San Francisco CA 94143; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

**(57) Comprehensive Analysis of Conventional and Molecular Cytogenetic Studies for 380 Newly Diagnosed Acute Lymphoblastic Leukemia Patients**

O. Khojah\*, M. Al-Majed\*, S. Barri\*, S. Ramdan\*\*, S. Khalil\*\*  
\* Pathology Department, College of Medicine, King Saud University, Riyadh, SA  
\*\* Department of Pathology & Laboratory Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, SA



**(58) Excellent Congruence in Ploidy Assessment of Acute Lymphoblastic Leukemia between Molecular Cytogenetic Analysis and Flow Cytometry Technique**

O. Khojah\*, M. Al-Majed\*, F. Rawas\*\*, S. Khalil\*\*

\* Pathology Department, College of Medicine, King Saud University, Riyadh, SA; \*\* Department of Pathology & Laboratory Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, SA

**(59) Immunophenotypic Characterization of Early Thymic Precursor (ETP) Acute Lymphoblastic Leukemia**

O. Illarionova<sup>1</sup>, T. Verzhbitskya<sup>2</sup>, G. Tsaur<sup>2</sup>, L. Fechina<sup>2</sup>, E. Boychenko<sup>3</sup>, S. Plyasunova<sup>1</sup>, A. Karachunsky<sup>1</sup>, A. Popov

1) Dederal Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia; 2) Regional Children's Hospital, Ekaterinburg, Russia; 3) Children's City Hospital 1, St. Petersburg, Russia

**(60) Primary Adult Acute Lymphoblastic Leukemic Cells Reliably Engraft and Grow in Immunodeficient Mice**

B. Heckl<sup>1</sup>, M. Carlet<sup>1</sup>, M. Grunert<sup>1</sup>, B. Vick<sup>1,2</sup>, C. Roof<sup>3</sup>, C. Junghan<sup>3</sup>, K. Spiekermann<sup>2,4</sup>, W. Hiddemann<sup>2,4</sup>, I. Jeremias<sup>1,2,5</sup>

<sup>1</sup>Helmholtz Zentrum München; <sup>2</sup>German Cancer Consortium (DKTK), Partner site Munich; <sup>3</sup>Department of Internal Medicine III, University of Rostock; <sup>4</sup>Department of Internal Medicine III, Ludwig Maximilians University (LMU), Munich; <sup>5</sup>Dr. von Haunersches Kinderspital, LMU Munich; all in Germany

**V. ALL – THERAPY**

**(61) Detection Of Minimal Residual Disease (MRD) In Young Adults With Acute Lymphoblastic Leukemia (ALL) (The Protocol ALL-MB- MINSK 2010)**

N. Mihal, A. Lelei, L. Movchan, E. Staliarova, I. Tarasevich, I. Emelianova, N. Kasakevich, M. Belevtsev, and O. Aleinikova

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Republic of Belarus

**(62) Targeting IAPs in Childhood Acute Lymphoblastic Leukemia – A Promising Therapeutic Option?**

M. Meyer, J. Zinngrebe, K.-M. Debatin and L.-H. Meyer

Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany

**(63) VEGF as a Novel Target Treating CNS Leukemia**

V. Münch<sup>1,2</sup>, L. Trentin<sup>1</sup>, J. Herzig<sup>1</sup>, S. Demir<sup>1,2</sup>, F. Seyfried<sup>1</sup>, J.M. Kraus<sup>3</sup>, H.A. Kestler<sup>3</sup>, R. Köhler<sup>4</sup>, T.F.E. Barth<sup>5</sup>, G. te Kronnie<sup>6</sup>, K.-M. Debatin<sup>1</sup>, and L.H. Meyer<sup>1</sup>

<sup>1</sup> Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Germany; <sup>2</sup> International Graduate School of Molecular Medicine, Ulm University, Germany; <sup>3</sup> Institute of Medical Systems Biology, Ulm University, Germany; <sup>4</sup> Institute of Human Genetics, University of Heidelberg, Germany; <sup>5</sup> Institute for Pathology, Ulm University, Germany; <sup>6</sup> Laboratory of Oncohematology, Department of Women's and Children's Health, University of Padua, Italy





**(64) Targeting the ER-Mitochondrial Interface of Cell Death Sensitizes Leukemia Cells towards Cytostatics**

F. Kocczian<sup>1</sup>, J. Vomacka<sup>2</sup>, B. Vick<sup>3</sup>, B. Hettich<sup>1</sup>, U. Kazmaier<sup>4</sup>, S. Sieber<sup>2</sup>, I. Jeremias<sup>3</sup>, A. Vollmar<sup>1</sup>, and S. Braig<sup>1</sup>

<sup>1</sup>Dept. of Pharmaceutical Biology, LMU Munich, Germany. <sup>2</sup>Dept. of Chemistry, TU Munich, Germany. <sup>3</sup>Research Unit Gene Vectors, Helmholtz Center Munich, Germany. <sup>4</sup>Inst. of Organic Chemistry, Saarland University, Saarbrücken, Germany

**(65) Targeting Mutant p53 in Acute Lymphoblastic Leukemia as a Novel Therapeutic Strategy**

S. Demir<sup>1</sup>, Q. Sun<sup>1</sup>, E. Tausch<sup>1</sup>, S. Stilgenbauer<sup>1</sup>, G. te Kronnie<sup>2</sup>, L. Wiesmüller<sup>1</sup>, G. Selivanova<sup>3</sup>, K.-M. Debatin<sup>1</sup>, and L. H. Meyer<sup>1</sup>

<sup>1</sup>Ulm University Medical Center, Ulm, Germany; <sup>2</sup>Dept. of Women's and Childrens' Health, University of Padova, Padova, Italy; <sup>3</sup>Dept. of Microbiology, Tumor and Cell Biology, Karolinska Inst., Stockholm, Sweden

**(66) Droplet Digital Pcr Analysis for Diagnosis and Minimal Residual Disease Monitoring in Adult PH+ Acute Lymphoblastic Leukemia**

N Coccaro, L Anelli, A Zagaria, G Tota, P Orsini, L Impera, C Brunetti, A Minervini, CF Minervini, C Cumbo, P Casieri, D Pastore, P Carluccio, G Specchia, and F.Albano  
Hematology - DETO, University of Bari, Bari, Italy

**(67) A Preclinical PDX Model for Patients' Minimal Residual Disease in ALL**

E. Özdemir<sup>1</sup>, C. Ziegenhain<sup>2</sup>, R. Panzer-Grünmayer<sup>3</sup>, W. Enard<sup>2</sup>, and I. Jeremias<sup>1,4,5</sup>

<sup>1</sup>Department of Gene Vectors; Helmholtz Zentrum München; Germany; <sup>2</sup>Anthropology and Human Genomics, Faculty of Biology, Ludwig-Maximilians-Universität München, Germany; <sup>3</sup>Children's Cancer Research Institute and St. Anna Kinderspital, Medical University of Vienna, Austria; <sup>4</sup>German Cancer Consortium (DKTK), Partner site Munich, Germany; <sup>5</sup>Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität München, Germany

**(68) XIAP is an Attractive Therapeutic Target for all as Validated in Innovative Genetically Engineered Patient-Derived Xenograft Models**

J.Vergalli<sup>1</sup>, M.Carlet<sup>1</sup>, T.Hoffmann<sup>4</sup>, M.Roth<sup>4</sup>, J.Zuber<sup>4</sup> and I.Jeremias<sup>1,2,3</sup>

<sup>1</sup> Helmholtz Zentrum München (HMGU), 81377 Munich, Germany; <sup>2</sup> Ludwig-Maximilians-Universität München, 80337 Munich, Germany; <sup>3</sup> German Cancer Consortium (DKTK), Partner Site Munich, Germany; <sup>4</sup> Research Institute of Molecular Pathology (IMP), 1030 Vienna, Austria

**(69) Clones with and without Sensitivity towards Treatment In Vivo Co-Exist within a Single Sample of a Patient with ALL**

Cornelia Finkenzeller<sup>1</sup>, Michela Carlet<sup>1</sup>, Sebastian Vosberg<sup>2,3</sup>, Martin Neumann<sup>3,4</sup>, Kristoffer Riecken<sup>5</sup>, Kerstin Cornils<sup>5</sup>, Boris Fehse<sup>5</sup>, Claudia D Baldus<sup>3,4</sup>, Philipp A. Greif<sup>2,3</sup> and Irmela Jeremias<sup>1,3,6</sup>

<sup>1</sup> Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; <sup>2</sup> Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany; <sup>3</sup> German Cancer Consortium (DKTK), Partner site Munich, Germany; <sup>4</sup> Department of Hematology, Oncology and Tumor Immunology, Charité, University Medical Center, Berlin, Germany; <sup>5</sup> Research Department Cell and Gene Therapy, Clinic for Stem Cell Transplantation, University Medical Center Hamburg- Eppendorf, Hamburg, Germany; <sup>6</sup> Dr. von Haunersches Kinderspital, Ludwig-Maximilians-University, Munich, Germany



## VI. APL – THERAPY

### **(70) Impact of First-Line Arsenic Trioxide and Retinoic Acid Treatment on Outcome in Therapy-Related Acute Promyelocytic Leukemia Patients**

S. Kayser<sup>1,2</sup>, J. Krzykalla,<sup>3</sup> K. Norsworthy,<sup>4</sup> M. Elliott,<sup>5</sup> D. Grimwade,<sup>6</sup> R.K. Hills,<sup>7</sup> P. Gonzales,<sup>8</sup> Z. Ráčil,<sup>9</sup> J. Mayer,<sup>9</sup> M. R. Baer,<sup>10,11</sup> J. et al.

<sup>1</sup>Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany; <sup>2</sup>Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; <sup>3</sup>Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany; <sup>4</sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; <sup>5</sup>Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA; <sup>6</sup>Department of Medical & Molecular Genetics, King's College London, Faculty of Life Sciences and Medicine, UK; <sup>7</sup>Cardiff University School of Medicine, Cardiff, United Kingdom; <sup>8</sup>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>9</sup>Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; <sup>10</sup>University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; <sup>11</sup>Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA;

### **(71) G-DRG 2016 Based Cost-Effectiveness Analysis of Arsenic Trioxide (ATO) and All-Trans Retinoid Acid (ATRA) in Patients with Acute Promyelocytic Leukemia Treated within the APL0406 Trial**

S.Schönsteiner, K.Kreppl, N.Becker, A.Benner, B.Röhrer, W.Fiedler, P.Brossart, B.Hertenstein, HR Salih, M.Wattad, M.Lübbert, S.Kremers, C.Brandts, M.Hänel, N.Schmitz, H.Link, A.Ganser, G.Ehninger, H.Döhner, F.Lo-Coco, U.Platzbecker, RF Schlenk for the German APL0406 investigators

### **(72) Comparative Genomic Analysis of PML and RARA Breakpoints in Paired Diagnosis/Relapse Samples of Patients with Acute Promyelocytic Leukemia Treated with ATRA and Chemotherapy**

L. Iaccarino<sup>1,2</sup>, T. Ottone<sup>1,2</sup>, SS K. Hasan<sup>3</sup>, M. Divona<sup>1</sup>, L. Cicconi<sup>1</sup>, S. Lavorgna<sup>1,2</sup>, G. Basso<sup>4</sup>, E. Such<sup>5</sup>, M. Bocchia<sup>6</sup>, E. M. Rego<sup>7</sup>, D. Grimwade<sup>8</sup>, M. T. Voso<sup>1</sup> and F. Lo-Coco<sup>1,2</sup>.

<sup>1</sup>Department of Biomedicine and Prevention, Università di Roma "Tor Vergata", Rome, Italy. <sup>2</sup>Laboratory of Neuro-Oncohematology, Fondazione Santa Lucia I.R.C.C.S, Rome, Italy. <sup>3</sup> Department of Medical Oncology ACTREC, Tata Memorial Centre Navi Mumbai, India. <sup>4</sup>Department of Women's and Children's Health, University of Padova, Padova, Italy. <sup>5</sup>Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain. <sup>6</sup>Department of Medicine and Immunological Sciences, Division of Hematology and Transplants, University of Siena, Siena, Italy. <sup>7</sup>Department of Internal Medicine, Medical School of Ribeirão Preto and Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil. <sup>8</sup>Department of Medical and Molecular Genetics, King's College London School of Medicine, London, United Kingdom

## VII. PEDIATRIC ACUTE LEUKEMIAS

### **(73) FLT3-ITD Allelic Ratio and Length Predict Overall Survival in Childhood AML**

D. Cucchi<sup>1,2</sup>, V. de Haas<sup>3</sup>, B. Denys, K. Vandepoele<sup>4</sup>, J. Philippé<sup>4</sup>, S. Zweegman<sup>2</sup>, GJ. Kaspers<sup>1,5</sup>, G. Ossenkoppele<sup>2</sup>, GJ. Schuurhuis<sup>2</sup>, J. Cloos<sup>1,2</sup>, E. Sonneveld<sup>3</sup>.

<sup>1</sup>Pediatric Hematology and <sup>2</sup>Hematology, VU University Medical Center, Amsterdam, The Netherlands; <sup>3</sup>Dutch Childhood Oncology Group, The Hague, The Netherlands; <sup>4</sup>Laboratory for Molecular Diagnostics-Hematology, Ghent University Hospital, Ghent, Belgium; <sup>5</sup>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands



**(74) Anthracycline Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia**

J.C. Sagi, J. C. Sagi, N. Kutszegi<sup>11</sup>) G.T. Kovacs<sup>2</sup>), C. Szalal<sup>3</sup>) D. J. Erdelyi<sup>2</sup>) and A. F. Semsei<sup>1</sup>);

<sup>1</sup>)Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary; <sup>2</sup>) 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary; <sup>3</sup>) Heim Pal Children Hospital, Budapest, Hungary

**(75) The Place of Epigenetic Therapy in Childhood Acute Myeloid Leukemia**

A.Popa, V. Nemirovchenko, E. Flejshman, and G. Mentkevich

Dept. of Hematology/Oncology Pediatric Oncology and Hematology Research Institute, N.N.Blokhin Russian Cancer Research Center, Moscow, Russia

**(76) Activating CSF2RB Mutations Contribute to the Leukemic Transformation from TAM to ML-DS**

M. Labuhn<sup>1</sup>, K. Perkins<sup>2</sup>, M. El Kathib<sup>1</sup>, J. Taub<sup>3</sup>, D. Heckl<sup>1</sup>, P. Vyas<sup>2</sup>, J.H. Klusmann<sup>1</sup>

<sup>1</sup>Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; <sup>2</sup>MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK; <sup>3</sup>Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, USA

**(77) Crispr/A Screening to Identify Functional Long Noncoding RNAs in Pediatric Acute Myeloid Leukemia**

M. Ng<sup>1</sup>, L. Santer<sup>1</sup>, S. Emmrich<sup>1</sup>, A. Schwarzer<sup>1</sup>, D. Heckl<sup>1</sup> and J.H. Klusmann<sup>1</sup>

<sup>1</sup> Dept. of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

<sup>2</sup> Dept. of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany

**(78) NGS-BASED Molecular Characteristics of AML with t(16;21)(p11;q22)/FUS-ERG: Additional Molecular Events and First Case of ASXL1 Mutation In HSCT Donor Cells**

E. Zerkalenkova, A. Kazakova, Yu. Olshanskaya, L. Shelihova, G. Novichkova, M. Maschan, A. Maschan  
Lab. of Cytogenetics and Molecular Genetics, Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

**(79) Anti-Leukemia Activity of the BCL-2 INHIBITOR ABT-199 in Pediatric BCP-ALL is Predicted by BCL-2/MCL-1 Expression Indicating Treatment Response**

F. Seyfried, R. Hörl, S. Demir, S. Köhrer, A. Scheffold, S. Stilgenbauer, K-M. Debatin, L.H. Meyer

Dept. of Pediatrics and Adolescent Medicine and Dept. of Internal Medicine III, Ulm University Medical Center, Ulm, Germany

**(80) IKZF1 Deletions are Independent Prognostic KZF in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia in Russia**

G. Tsaur<sup>1,2,3,4</sup>, A. Druy<sup>2,5</sup>, A. Solodnikov<sup>2,4</sup>, A. Popov<sup>5</sup>, A. Shapochnik<sup>6</sup>, A. Vlasova<sup>1,4</sup>, L. Vakhonina<sup>1,2</sup>, T. Riger<sup>1,2</sup>, T. Verzhbitskaya<sup>1,2</sup>, Yu. Olshanskaya<sup>5</sup>, Shorikov E.V.<sup>7</sup>, Arakaev O.R.<sup>1,2</sup>, Saveliev L.I.<sup>1,2,4</sup>, Fechina L.G.<sup>1</sup>

<sup>1</sup>Regional Children's Hospital No 1, Ekaterinburg, 620149, Russian Federation; <sup>2</sup>Research Institute of Medical Cell Technologies, Ekaterinburg, 620026, Russian Federation; <sup>3</sup>Ural Federal University named after the First president of Russia B.N. Yeltsin, Ekaterinburg, 620002, Russian Federation; <sup>4</sup>Ural State Medical University, Ekaterinburg, 620030, Russian Federation; <sup>5</sup>Federal Research Institute of Pediatric Hematology, Oncology, and Immunology named after Dmitriy Rogachev, Moscow, 117997, Russian Federation; <sup>6</sup>Orenburg Regional Clinical Oncological Dispensary, Orenburg, 460021, Russian Federation; <sup>7</sup>Morozov Pediatric Municipal Hospital, Moscow, 119049, Russian Federation



**(81) Impact of WT1 Mutations in Pediatric Acute Myeloid Leukemia – Role of Co-Mutations**

Naghmeh Niktoreh-Mofrad<sup>1</sup>, Christiane Walter<sup>1</sup>, Nils von Neuhoff<sup>1</sup>, Mareike Rasche<sup>1</sup>, Ursula Creutzig<sup>2</sup>, Dirk Reinhardt<sup>1</sup>

<sup>1</sup> University Children's Hospital Essen; <sup>2</sup> Hannover Medical School, Germany

**(82) Prognostic Value of Flow Cytometric Minimal Residual Disease Assessment in Infant Acute Lymphoblastic Leukemia**

A. Popov<sup>1</sup>, T. Verzhbitskaya<sup>2</sup>, G. Tsauro<sup>2</sup>, L. Movchan<sup>3</sup>, M. Belevtsev<sup>3</sup>, E. Shorikov<sup>4</sup>, N. Miakova<sup>1</sup>, D. Litvinov<sup>1</sup>, K. Kondratchik<sup>4</sup>, E. Boychenko<sup>5</sup>, O. Aleinikova<sup>3</sup>, A., Karachunsky<sup>1</sup>, L. Fechina<sup>2</sup>

<sup>1</sup>Federal Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia; <sup>2</sup>Regional Children's Hospital, Ekaterinburg, Russia; <sup>3</sup>Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus; <sup>4</sup>Morozov City Children's Hospital, Moscow, Russia; <sup>5</sup>Children's City Hospital 1, St., Petersburg, Russia

**(83) Recapitulating the Developmental Stage-Specific Effects of Down Syndrome-Leukemia-Associated Gata1s Mutations in Human Cells with Genome Editing**

S. Gialesaki<sup>1</sup>, L. Stachorski<sup>1</sup>, D. Heckl<sup>1\*</sup>, J.H. Klusmann<sup>1\*</sup>

<sup>1</sup>Ped. Hematology & Oncology, Hannover Medical School; \* contributed equally

**VIII. IMMUNOTHERAPY OF ACUTE LEUKEMIAS**

**(84) Elimination of Cells from Patients with Different Subtypes of AML by Dual-Targeting Triplebody 33-16-123 (SPM-2)**

T. Braciak<sup>1</sup>, N. Fenn<sup>2</sup>, S. Wildenhain<sup>2</sup>, C. Schiller<sup>2</sup>, C. Roskopf<sup>1</sup>, I. Schubert<sup>3</sup> U. Jacob<sup>4</sup>, KP Hopfner<sup>2</sup>, M. Aigner<sup>2</sup>, A. Mackensen<sup>5</sup>, M. Subklewe<sup>6</sup>, K. Spiekermann<sup>6</sup>, GH Fey<sup>3</sup> and F Oduncu<sup>1</sup>

<sup>1</sup>Section of Hematology/Oncology, Medizin. Klinik & Poliklinik IV, Ludw. Max. Univ. Munich; <sup>2</sup>Dptmt of Biochemistry, Gencenter, Ludw. Max. Univ. Munich; <sup>3</sup>Deptmt of Biology, Friedr. Alex. Univ. Erlangen-Nuremberg; <sup>4</sup>Westend Innovation Munich; <sup>5</sup>Deptmt of Internal Medicine V, Hematology/Oncology, Univ. Erlangen-Nuremberg; <sup>6</sup>Deptmt of Internal Medicine III, Haematology/Oncology, Ludw. Max. Univ. Munich, Germany

**(85) HLA-DPB1 Specific T-CELL Receptors as a Novel Approach in Allogeneic T-CELL Therapy of Leukemias**

S. Vatter, M. Zwerger, C. Mirbeth, M. Siebörger, W. Herr, S. Thomas

Department of Internal Medicine III, University Hospital Regensburg, and Regensburg Center for Interventional Immunology, University of Regensburg, Regensburg, Germany

**(86) Influence of Cytoreductive and Immunomodulatory Drugs on Bispecific T-Cell Engager-Based Approaches in AML**

C. Krupka<sup>1,2</sup>, B. Lindl<sup>1,2</sup>, R. Kischel<sup>3</sup>, P. Kufer<sup>3</sup>, FS. Lichtenegger<sup>1,2</sup>, T. Köhnke<sup>1,2</sup>, C. Augsburg<sup>1,2</sup>, T. Altmann<sup>1,2</sup>, K. Spiekermann<sup>1</sup>, W. Hiddemann<sup>1</sup>, M. Subklewe<sup>1,2</sup>

<sup>1</sup>Department of Internal Medicine III, Klinikum der Universität München, LMU Munich, Germany; <sup>2</sup>Clinical Cooperation Group Immunotherapy, Helmholtz Zentrum München, Munich, Germany; <sup>3</sup>AMGEN Research (Munich) GmbH, Munich, Germany



## **IX. IMMUNOTHERAPY OF ACUTE LEUKEMIAS**

### **(87) Single Center Experience of Auto Sct in Children with HR AML in CR1**

N.Kavardakova, J. Bazaluk, O. Ryzhak, Y. Kovgan, O. Leontieva, O. Lysitsia, S. Matsibokh, I. Stetsiuk, A.Volkova, S. Hranatska, I. Shergina, J. Filevska, and S. Donska  
National Ukrainian Children`s Hospital "Ochmatdyt", Center of Pediatric Oncohematology and BMT. Kiev, Ukraine

### **(88) Results of RIC with Haploidentical HSCT from Related Donors in Children with Very High Risk AML**

N. Subbotina, I. Dolgopolov, V. Daylidite, V. Boyarshinov, and G. Mentkevich  
Institute of Pediatric oncology and hematology, N.N. Blokhin's Russian Cancer Research Center, Moscow, Russia

### **(89) Clinical Outcome of Myeloid Sarcoma in Adult Patients and Effect of Allogeneic Stem Cell Transplantation. Results from a Multicenter Survey**

D. Lazzarotto (1), A. Candoni (1), C. Fili (1), M.E. Zannier (1), F. Forghieri (2), L. Pagano (3), A. Busca (4), G. Ventura (1), et al.

(1)Hematology and BMT section, University of Udine, Italy. (2)Dpt of Hematology, University of Modena and Reggio Emilia, Italy. (3)Dpt of Hematology, UCSC, Rome, Italy. (4)Dpt of Hematology, Ospedale S. Giovanni Battista, Torino, Italy.

### **(90) Post-Transplant CY for GVHD Prophylaxis in Patients with Advanced Leukemia**

Mikhail Y. Drovokov, Vera A. Vasilyeva, Darya S. Dubnyak, Olga M. Koroleva, Ekaterina D. Mikhalcova, Natalia N. Popova, Zoya V. Konova, Larisa A. Kuzmina, Elena N. Parovichnikova, Valery G. Savchenko  
BMT Department, National Research Center For Hematology, Moscow, Russia

### **(91) FLAG-IDA Regimen as Bridge Therapy to Allotransplant in Refractory/Relapsed AML Patients: A Single Center Experience**

M Delia\*, D Pastore, P Carluccio, C Pasciolla, A Ricco, A Russo Rossi, A Mestice, F Albano, G Specchia. Hematology - University of Bari, Bari, Italy

### **(92) Whole Exome Sequencing Reveals Acquisition of mutations Leading to the Onset of Donor Cell Leukemia after Hematopoietic Transplantation. A Model of Leukemogenesis**

Julia Suárez-González<sup>1,2\*</sup>, Carolina Martínez-Laperche<sup>1,2\*</sup>, Nerea Martínez<sup>3</sup>, Gabriela Rodríguez-Macías<sup>1,2</sup>, Mi Kwon<sup>1,2</sup>, Pascual Balsalobre<sup>1,2</sup>, David Serrano<sup>1,2</sup>, Miguel Angel Piris<sup>3</sup>, Jorge Gayoso<sup>1,2</sup>, Jose Luis Díez Martín<sup>1,2</sup>, Ismael Buño<sup>1,2</sup>. (\*) JS-G and CM-L have contributed equally to this work.

Servicio de Hematología y Hemoterapia. Hospital General Universitario Gregorio Marañón, Madrid, España. <sup>2</sup> Instituto de Investigación Sanitaria. Hospital General Universitario Gregorio Marañón, Madrid, España. <sup>3</sup>Pathology Department, Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain

## **X. IMMUNOTHERAPY OF ACUTE LEUKEMIAS**

### **(93) Results of the Decider Trial (AML5G 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without ATRA in Newly Diagnosed Elderly Non-Fit AML Patients**

M. Lübbert<sup>1</sup>, O. Grishina<sup>1</sup>, C. Schmoor<sup>1</sup>, R.F. Schlenk<sup>2</sup>, M. Crysandt<sup>3</sup> et al.

<sup>1</sup>University Freiburg Medical Center, Freiburg, Germany <sup>2</sup>University Hospital Ulm, Ulm, Germany <sup>3</sup>RWTH Aachen University Medical School, Aachen, Germany



**(94) Correlative Biomarkers of Response to Venetoclax (VEN) in Combination with Chemotherapy or Hypomethylating Agents (Hma) in Elderly Untreated Patients with Acute Myeloid Leukemia (AML)**

B. Chyla<sup>1</sup>, R. Popovic<sup>1</sup>, J. Potluri<sup>1</sup>, J. Hayslip<sup>1</sup>, X. Huang<sup>1</sup>, M. Mabry<sup>1</sup>, and A. Bhatena<sup>1</sup>  
<sup>1</sup>AbbVie, Inc, North Chicago, USA

**(95) Safety and Efficacy of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Treatment-Naive Patients (PTS) Aged ≥65 Years with Acute Myeloid Leukemia (AML)**

A.H. Wei<sup>1</sup>, S.A. Strickland<sup>2</sup>, G.J. Roboz<sup>3</sup>, J-Z. Hou<sup>4</sup>, W. Fiedler<sup>5</sup>, T.L. Lin<sup>6</sup>, R.B. Walter<sup>7</sup>, A. Enjeti<sup>8</sup>, K.M. Fakouhi<sup>9</sup>, D.E. Darden<sup>9</sup>, M. Dunbar<sup>9</sup>, S. Agarwal<sup>9</sup>, A.H. Salem<sup>9</sup>, M. Mabry<sup>9</sup>, J. Hayslip<sup>9</sup> <sup>1</sup>The Alfred Hospital and Monash University, Melbourne, Australia; <sup>2</sup>Vanderbilt-Ingram Cancer Center, Nashville, USA; <sup>3</sup>Weill Cornell Medical College, New York, USA; <sup>4</sup>UPMC Cancer Center, Pittsburgh, USA; <sup>5</sup>Hubertus Wald University Cancer Center, Hamburg, Germany; <sup>6</sup>University of Kansas Medical Center, Kansas City, USA; <sup>7</sup>University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA; <sup>8</sup>Calvary Mater Hospital Newcastle, Waratah, Australia; <sup>9</sup>AbbVie, Inc, North Chicago, USA

**96) Vadastuximab Talirine (33a) plus a Hypomethylating Agent (HMA): A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)**

Roland B. Walter, MD, PhD, MS<sup>1</sup> and Amir T. Fathi, MD<sup>2</sup> on behalf of the SGN33A-001 study team  
<sup>1</sup>Fred Hutchinson Cancer Research Center, <sup>2</sup> Massachusetts General Hospital Cancer Center, Boston, USA

## **XI. IMMUNOTHERAPY OF ACUTE LEUKEMIAS**

**(97) Impact of Mucosal Colonization with MDR/XDR Microorganisms on Risk of Febrile Neutropenia In Patients With Acute Myeloid Leukemia**

I. Stoma, I. Iskrov, I. Lendina, V. Chernyak  
Department of Hematology №3, City Clinical Hospital №9, Minsk, Belarus

## **XII. LEUKEMIA MICROENVIRONMENT**

**(98) Extracellular Vesicle (EV) TRANSFER within the BM NICHE in FLT3-ITD+ Acute Myeloid Leukemia (AML)**

J. Hecker \*1, A.-K. Garz \*1,2, L. Jacobs 1, M.-T. Weickert 1, A. Krikoni 3, T. Schröder 4, C. Peschel 1, B. Giebel 3, U. Keller 1,2, K. S. Götzte 1,2<sup>1</sup>  
Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany  
<sup>2</sup>German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; <sup>3</sup>Department of Transfusion Medicine, University of Essen, Germany; <sup>4</sup>Department of Medicine III, University of Düsseldorf, Germany



## GENERAL INFORMATION

- Scientific Program:** **Sunday, February 19 – Wednesday, February 22, 2017**
- Venue:** **Klinikum Großhadern  
Hörsaaltrakt  
Marchioninistraße 15  
81377 Munich, Germany**
- Official Language:** English
- Scientific Program:** All Main Sessions, Satellite Symposia and Meet-the-Professor Sessions are **CME-certified sessions**. Take the opportunity and hear the internationally most recognized experts, discuss the most relevant clinical questions, and **earn CME credits**.
- Free Oral and Poster Presentation:** Additional contributions will be presented in an oral session (Best of Free Contributions) and as posters. **Poster Session** will be held on **Monday, Feb. 20, 2017, Best of Free Contributions' Session** will be held on **Tuesday, Feb. 21, 2017**.
- How to Register:** **All registrations must be done by e-mail**  
**The easiest way to register is by electronic registration via our website: [www.acute-leukemias.de](http://www.acute-leukemias.de)**
- Official Homepage:** All necessary details about the registration modus, registration fees, and registration deadlines are listed below **and** at **[www.acute-leukemias.de](http://www.acute-leukemias.de)**
- Organizing Office:** **Beate Buske-Kosel, M.A.**  
Am Webstuhl 5  
D-59227 Ahlen, Germany  
**Phone:** +49-(0)2382-76 01 457  
**Fax:** +49-(0)2382-76 01 458  
**e-mail:** [info@acute-leukemias.de](mailto:info@acute-leukemias.de)
-



---

## GENERAL INFORMATION

- Registration Deadlines and Registration Fee:**      **“Early” registration fee: €195**  
Registration and payment before December 1, 2016  
**“Advance” registration fee: €220**  
Registration and payment: after December 1, 2016,  
but before Feb 13, 2017  
**“Late” and “On-site” registration fee: €280**  
Registration and payment after Feb 13, 2017
- Method of Payment:**      **Advance payment can be made by check or wire transfer to following bank account:**  
**Account Holder:** Verein für Leukämieforschung und Therapie e.V.  
**Bank:** Sparkasse Münsterland Ost  
**Bank Address:** Rothenburg 7, 48135 Münster, DE  
**IBAN:** DE 64400 501 5000 1900 2468  
**BIC-Code:** WELADED1MST  
**To identify your payment correctly** all payments must carry the **name of the participant** and the **key word** ACUTE LEUKEMIAS XVI – 2017  
**Please note** On-site payment is only possible cash or by check; payment by credit card is not possible!
- Services Included:**      The registration includes admission to all scientific sessions, the reception on Sunday evening, February 19, 2017, and the Abstract Booklet
- Free Access to All Sessions:** Please note that also participants who are not subject to the registration fee are asked to officially register:
- Members of the Scientific Committees
  - Participating Members of the AMLCG Study Group
  - Members of the LMU and TUM Munich
  - Members of the HelmholtzZentrum Munich
  - Members of the TZM Project Group „Akute Leukämie, MDS und MPS“
  - Former Members of the SFB 684 Munich
  - Students and Nurses (confirmation required)
  - Invited Representatives of the Participating Corporate Partners (confirmation required)
  - Faculty (Invited Speakers and Chairman: No additional registration required, automatically registered.
-





**PRIZES AND AWARDS:**

**Awards:**



*Best of Free  
Contributions  
Awards 2017*



*Poster Awards  
2017*



*Leukemia Clinical  
Research Award  
2017*



Again, two **Poster Awards** of € 500 and the **3 Best-of-Free-Contributions Awards** will be granted to young scientists presenting their poster at ISALXVI. A jury, consisting of 2 faculty members, will evaluate the posters and decide about the 2 Poster Prize and the 3 Best-of-Free-Contributions Award winners.

The **Leukemia Clinical Research Award 2017 (LCRA)** which is endowed with € 7,500 will be granted to a young investigator presenting a scientific paper in the field of clinical or preclinical research. Candidates must submit their application until the submission deadline, **December 31, 2016**.

**Prize Giving Ceremony:**

**Main Session IX:** Prize giving Ceremony for the 2 **Poster Awards**, the **3 Best of Free Contribution Awards** (5' oral presentation each), and the **LCRA Award 2017** followed by a 15' oral contribution of the LCRA winner.

**Abstract Submission:**

**Deadline, November 15, 2016.**

**Poster Viewing:**

**Monday, February 20, 2017: 13.00 - 18.00**  
**Tuesday, February 21, 2017: 09.00 and 18.00**

**Poster Discussion  
Session:**

**All poster** presenters are expected to personally\* **attend ISALXVI and participate in**

**MS IX (Poster Discussion Session) on Monday, February 20, 2017: 15.45 - 17.00**

to allow all participants and the jury to talk to the presenters.

(\*In case a poster presenter is not able to personally attend the symposium and Main Sessions V and IX she/he is asked to provide a person who can take over her/his part. Please inform the Organizing Office about this change in advance)

**Posters** will be presented on the **Upper Floor** of the symposium venue. A cheese and wine tasting is organized, where a great variety of Bavarian cheese will be served.



---

**CERTIFICATE OF ATTENDANCE:**

A certificate of attendance will be available on-site for all officially registered participants of the International Symposium **ACUTE LEUKEMIAS XVI (ISALXVI)**.

An application for **CONTINUING MEDICAL EDUCATION (CME)** of **ISALXVI** has been made to the following institutions:

• *The Bayerische Landesärztekammer (BLAEK) has granted the following CME points:*

<b>Sunday</b> , February 19, 2017:	4 pts.
<b>Monday</b> , February 20, 2017:	8 pts.
<b>Tuesday</b> , February 21, 2017:	8 pts.
<b>Wednesday</b> , February 22, 2017:	5 pts.

• *European Accreditation Council for Continuing Medical Education (EACCME)*

**HOTELS AND ACCOMODATION FACILITIES FOR NATIONAL and INTERNATIONAL ATTENDEES**

Thank you for attending **ISALXVI** 2017. To facilitate your planning and help you make your stay as pleasant as possible, the **Munich Tourism Team** of **München Tourismus** is happy to offer you a great variety of Munich hotels, pensions, guesthouses and youth hostels. According to your preferences and criteria they will try to find for you the best offer at the most reasonable price performance ratio.

**Service Requests can be either made by Phone, Fax or Email**

**Phone** +49 89 233-96500

Monday –Friday: 09.00 – 17.00 h

**Fax:** +49 89 233-30030

**Email:** [tourismus.gs@muenchen.de](mailto:tourismus.gs@muenchen.de)

**HOTELS AND ACCOMODATION FACILITIES FOR NATIONAL and INTERNATIONAL INVITED SPEAKERS AND FACULTY:**

To facilitate your planning and help you make your stay most pleasant and comfortable, the **ISALXVI ORGANIZING OFFICE TEAM** ([info@acute-leukemias.de](mailto:info@acute-leukemias.de)) is happy to assist you personally in everything related to your stay and will contact you unrequested during the early planning phase.

---



SUNDAY, February 19, 2017, 20.00 – 22.00

## Social Event

### *Welcoming Reception at LeMeridien*



#### Address:

#### **Hotel LeMERIDIEN**

Bayerstraße 4  
D-80335 Munich

#### Admission: (Free Access)

**All officially registered participants** of the meeting, accompanying persons, and participating corporate partners are cordially invited to participate in the **Welcoming Reception** which will be held in the banqueting hall of **LeMERIDIEN**.

*All ISALXVI participants* interested in participating in the **Welcome Reception** are courteously asked to officially register in advance either at [www.acute-leukemias.de](http://www.acute-leukemias.de) or during the official opening hours at the **ISALXVI** registration desk.

#### Directions:

**U6** from Klinikum Großhadern to Marienplatz. From Marienplatz all **S- lines** which stop at Munich Main Station; from there it is a 5 minutes' walk from the south exit (see map on last page)



---

**TUESDAY, February 21, 20.00-22.30**

**Social Event**

***Social Evening and Festive Dinner at the Munich Castle***



**Address:**

Residenz München, Residenzstraße 1, 80333 München

**Admission:**

**Free Admission:**

Invited speakers, Chairmen, and Members of the Scientific Committees  
(Guaranteed Admission, Reservation Required)

**Regular Entry Fee:**

€20,00: Students, Nurses and Students

€30,00: All other officially registered Participants of ISALXVI

(Since space is limited **advance reservations** are obligatory either at [www.acute-leukemias.de](http://www.acute-leukemias.de) or during the official opening hours at the **ISALXVI** registration desk. Please note that priority will be given to those that register early)

**Directions:**

Detailed directions will be handed out at the registration desk or can be found at [www.acute-leukemias.de](http://www.acute-leukemias.de).

**A Shuttle Bus Service** will be available for all participants joining the Social Evening at the Munich Castle “Residenz” **after the end of Satellite II** starting from the symposium venue (Back entrance Hörsaaltrakt; Details will be announced on site)

---



---

## **CORPORATE SUPPORT**

**The support of ACUTE LEUKEMIAS XVI by the following companies is gratefully acknowledged (alphabetical order)**

### **Gold Circle Corporate Members (Satellite Symposia)**

**Amgen GmbH (SAT II: Sunday, Feb 19, 2017: 18.15–19.15)**

**Celgene GmbH (SAT VI: Tuesday, Feb 21, 2017: 16.30–17.30)**

**GILEAD Sciences GmbH (MTP I: Monday Feb 20, 2017: 13.00-13.45; AGIHO Grant)**

**Immune Pharmaceuticals (SAT III, Monday, Feb 20, 2017: 12.45-13.45)**

**Janssen Pharmaceutica NV (SAT V: Monday, Feb 20, 2017: 18.15-19.15)**

**Jazz Pharmaceuticals Germany GmbH (SAT VII: Tuesday, Feb 21, 2017: 17.45–18.45)**

**SHIRE GmbH (SAT I: Sunday, Feb 19, 2017: 17.00-18.00)**

**TEVA Pharma GmbH (SAT IV: Monday, Feb 20, 2017: 17.00-18.00)**

### **Silver Circle Corporate Members**

**Neovii Biotech GmbH (Leukemia Clinical Research Award 2017 Sponsor)**

**Novartis Pharma GmbH (MTP II: Tuesday, February 21, 2017: 13.00–13.30)**

### **Other Corporate Support**

**Sunesis Pharmaceuticals, Inc. (Sponsor Poster Prizes)**

### **German Research Sponsors:**

**Deutsche Forschungsgemeinschaft**

**ELN Foundation**

**Helmholtz Zentrum München**

### **Participating Companies in the Commercial Exhibition:**

**abbvie**

**Amgen GmbH**

**Celgene GmbH**

**GILEAD Sciences GmbH**

**Immune Pharmaceuticals**

**Janssen Pharmaceutica NV**

**Jazz Pharmaceuticals Germany GmbH**

**LIPOMED GmbH Deutschland**

**Neovii Biotech GmbH**

**Novartis Pharma GmbH**

**Pfizer Pharma GmbH**

**Roche Pharma AG**

**Seattle Genetics**

**SHIRE GmbH**

**Sunesis Pharmaceuticals, Inc.**

**TEVA Pharma GmbH**

---



**SCIENTIFIC LOCAL ORGANIZING COMMITTEE:**

Prof. Dr. Wolfgang Hiddemann, Munich (Chairman)  
Prof. Dr. Thomas Büchner, Münster (Chairman) †  
Prof. Dr. Karsten Spiekermann, Munich  
Prof. Dr. Irmela Jeremias, Munich  
Prof. Dr. Marion Subklewe, Munich  
PD Dr. Michael Fiegl, Munich  
Dr. Klaus Metzeler, Munich

**ORGANIZING OFFICE:**

Beate Buske-Kosel, M.A.  
Am Webstuhl 5  
D-59227 Ahlen  
Germany

**Phone:** +49-(0)2382-76 01 457

**Fax:** +49-(0)2382-76 01 458

**e-mail:** [info@acute-leukemias.de](mailto:info@acute-leukemias.de)

**COORDINATING OFFICE:**

Doris Braun

**Phone:** +49-89-4400 43986

**Fax:** +49-89-4400 43970

**Email:** [Doris.Braun@med.uni-muenchen.de](mailto:Doris.Braun@med.uni-muenchen.de)

---